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Esophageal cancer (EC) belongs to the ten most common cancers in the Netherlands, and 
accounts for 2.7% of all new cases in men and 1.1% in women1, 2. In 2010, approximately 
2000 new cases of EC were diagnosed in the Netherlands, an increase of 300% compared 
to 19891, 2. This is mainly caused by a higher prevalence of patients with gastroesophageal 
reflux disease (GERD) and Barrett’s dysplasia2, 3. Barrett’s mucosa is a premalignant condi-
tion that is almost exclusively related to the formation of adenocarcinoma in the distal 
one-third of the esophagus2.
EC is often diagnosed in an advanced stage of the disease with local or systemic spreading 
of cancer cells. Therefore, many patients are only eligible for palliative treatment with an 
unfavorable survival rate.
In patients selected on the basis of their overall condition and oncologic stage, a multimo-
dality approach with neoadjuvant chemoradiotherapy (CRT) is currently standard of care 
in a curative treatment policy4. Neoadjuvant CRT improves loco-regional control resulting 
in an improved resectability and a 5-years survival benefit of 13%. CRT is associated with 
a pathological complete response (pCR) of the tumor in 15-30% of patients4, 5. Neverthe-
less, surgical resection remains the most important potentially curative treatment, but is 
associated with substantial perioperative morbidity (40-60%) and in-hospital mortality 
(3-5%)6, 7, 8. Moreover, as many EC patients are above the age of 65 years, they usually 
present with co-morbidities and may be unfit for surgery.
The goal of the studies included in this thesis, is to identify the most important risk-factors 
during the various treatment phases in patients with EC who are selected for esophagectomy.
PreoPeratIve evaluatIon
EC predominantly occurs in the last decades of life; approximately 70% of the newly 
diagnosed patients were aged 65 years and over9. The predisposing factors for the devel-
opment of EC include smoking, GERD, obesity and alcohol consumption, which are also 
associated with a range of cardio-pulmonary disorders9. Consequently, in these patients 
a high prevalence of comorbidity exists, for example diabetes mellitus or chronic obstruc-
tive pulmonary disease, which can affect treatment outcome10. Surgeons will in general be 
more reluctant to perform major surgery in fragile and elderly patients. Frailty is increas-
ingly used as an important determinant for postoperative outcome and can be defined 
as the physiologic reserves and resistance to stressors of a patient11. In Chapter 2 the 
relation between advanced age (i.e. ≥ 70 years), comorbidity and postoperative outcome 
is evaluated.
Since esophagectomy is associated with considerable postoperative morbidity and 









































of appropriate surgical candidates are important steps to improve short-term outcome. 
Patients with an increased surgical risk and an expected prolonged recovery period might 
be considered curative radiotherapy or palliative therapy instead, in order to ensure 
quality of life. So it is pivotal for both the patient and the surgeon to realistically assess 
the expected impact of the surgical insult. However, reliable individual risk stratifications 
are still missing in daily practice. One of the most popular models in risk-assessment in 
surgical literature is the American Society of Anesthesiologists (ASA) score, which is a 
subjective estimate of organ system disease and preoperative fitness. In Chapter 3 we 
evaluated the ASA score and four other frequently used risk-prediction models to examine 
their ability to predict short-term postoperative outcome.
neoaDJuvant Crt
The role of neoadjuvant CRT in patients with EC has been debated for decades. Several 
trials have been published in recent years with conflicting results with regard to long-term 
survival, but with a growing evidence for a beneficial effect of neoadjuvant CRT4, 12-14. In 
particular, after publication of the CROSS trial, a large national randomized control trial 
in which our center participated, demonstrated a survival benefit of 13% at 5 years after 
neoadjuvant CRT4. Based on these results and previously published meta-analyses, most 
centers have chosen for standardization of neoadjuvant CRT in conditionally and onco-
logically suitable patients. The function of chemotherapy is to enhance the locoregional 
effect of radiotherapy, which lead to a potentially downsizing of the primary tumor, with 
improved resectability, and an increased chance to achieve pCR. Chemotherapy might 
also destroy possible micro-metastases leading to an improved long-term survival.
In contrast to these benefits, neoadjuvant CRT may be accompanied by a subsequently 
increased risk for adverse events. Commonly known side effects of a temporary nature in-
clude nausea, hair loss and neuropathic pain. However, more severe and life-threatening 
perioperative complications may also occur. Neoadjuvant CRT also seems to be associated 
with an enhanced risk of developing thromboembolic events (TEE’s)15. Chapter 4 evalu-
ates the incidence and impact of preoperative and postoperative TEE’s in patients treated 
with currently used neoadjuvant platinum-based CRT.
It has been reported that a combined therapy of neoadjuvant CRT and subsequent sur-
gery is associated with an increased risk for postoperative cardiopulmonary complications 
and anastomotic leakage16. By adding neoadjuvant CRT to a treatment that already has a 
considerable effect on the patient’s overall condition; concerns have been raised about 
the impact of neoadjuvant CRT on the postoperative course. Thoracic chemoradiotherapy 









































postoperative complications17, 18. The objective of Chapter 5 is to evaluate the effect of 
CRT on short-term outcomes by comparing the incidence of postoperative complications 
between patients with and without neoadjuvant CRT.
SurGery
Patients are considered for curative intended esophagectomy after a complete preop-
erative workup. Several surgical methods have been well explored, including transhiatal, 
transthoracic, or minimal invasive esophagectomy. Selection of an appropriate procedure 
depends on the location of the tumor, patient characteristics and preferences of the 
surgeon. In general, transhiatal esophagectomy (THE) is associated with a lower rate of 
(pulmonary) postoperative morbidity, while transthoracic esophagectomy (TTE) can be 
combined with a two-field lymphadenectomy resulting in improved locoregional con-
trol19. Compared to THE, TTE is generally accepted as standard procedure, although the 
pulmonary problems seem to be somewhat higher. The best preventable tool for pulmo-
nary-related problems remains an epidural anesthesia, even in the hands of surgeons 
who advocated a minimal invasive method. The fact that esophagectomy is technically 
challenging there is a need of state of the art diagnostic procedures, advanced surgical 
skills and training. Therefore, performing these surgical resections in is one reason why 
high volume centers have improved short-term and long-term outcomes20.
PoStoPeratIve ComPlICatIonS
In order to minimize the impact of comorbidity on outcome, it is of great importance 
to identify patients who are at the highest risk of developing a postoperative complica-
tion. Since we currently do not possess tools to reliably assess individual risk in daily 
practice, clinicians have to rely on careful physical examination, and routine postoperative 
diagnostics such as peripheral blood values. However, the value and degree of abnormal 
peripheral blood values after esophagectomy and their association with postoperative 
complications are not fully understood. Consequently, abnormal values after esophagec-
tomy could be expected to be due to malnutrition, comorbidity, the neoplasm itself, age, 
neoadjuvant therapy, or surgery-related conditions. Identifying patients with postopera-
tive complications based on deranged peripheral blood results is difficult. In Chapter 6 
our aim was to identify the prognostic value of early routine peripheral blood values in 










































Neoadjuvant CRT and subsequent surgery are both associated with the release of dif-
ferent pro-inflammatory cytokines21-23. However, the impact of a combined therapy on 
patient’s immunological response is not clear yet. Prognostic markers to assess the degree 
of pathological response in EC patients are still missing and could be used as a tool to 
individualize treatment strategy. Early response evaluation with functional imaging tech-
niques (PET/CT) are promising, but need further validation24. It has been suggested that 
cytokines could reflect the degree of pathological response from neoadjuvant CRT25, 26. 
Patients with pCR might be spared from probably meaningless surgical resection since this 
severe procedure is not related to improved long-term outcome in these patients27, 28. On 
the other hand, patients without pathological response might have been treated too long 
with CRT (early response evaluation) and may be planned earlier for definitive surgical re-
section. Furthermore, cytokine concentrations throughout different phases of treatment 
seemed to be related to complications caused by either CRT or subsequent surgery. Al-
though, cytokine concentrations have been extensively investigated after esophagectomy, 
their value in the context of multimodality treatment is far from clear29, 30. In Chapter 7 
we analyzed nine different cytokines concentrations during different phases (from start 
neoadjuvant CRT until the first postoperative week) in the treatment of EC patients to as-
sess the impact on patient’s immunological response and to identify for prognostic value 
on the degree of pathological response after CRT and complications caused by either CRT 
or subsequent surgery.
aIm of the theSIS
Patient characteristics and neoadjuvant CRT might interfere with short-term postop-
erative outcome. Appropriate selection of candidates for potentially curative treatment 
options and individualizing treatment strategies are important steps to improve the 
patient’s quality of life. The aim of the thesis is to identify risk-factors contributing to 
the development of perioperative complications throughout different phases in the treat-
ment of esophageal cancer patients. Early identification of these factors could provide us 
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extended esophagectomy in elderly patients with 
esophageal cancer: minor effect of age alone in 
determining the postoperative course and survival
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Background: Elderly patients who undergo esophagectomy for cancer often have a high 
prevalence of co-existing diseases, which may adversely affect their postoperative course. 
We determine the relation of advanced age (i.e. ≥ 70 years) with outcome and evaluate 
age as a selection criterion for surgery. Recommendations are given.
Patients and methods: Between January 1991 and January 2007, we performed a cura-
tive intended extended transthoracic esophagectomy in 234 patients with cancer of the 
esophagus. Patients were divided into two age-groups; < 70 years (group I; 170 pts) and 
≥ 70 years (group II; 64 pts).
results: Both groups were comparable regarding comorbidity (ASA-classification), tu-
mor and surgical characteristics. The overall in hospital mortality rate was 6.2% (5% vs. 
11%, p = 0.09). Advanced age was not a prognostic factor for developing postoperative 
complications (OR = 1.578; 95%CI = 0.857 to 2.904; p = 0.143). The overall number of 
complications was equal with 58% in group I vs. 69% in group II (p = 0.142). Moreover, 
the occurrence of complications in elderly patients did not influence survival (p = 0.174). 
Recurrences developed more in patients < 70 years (58% vs. 42%, p = 0.028). The overall 
5-year survival was 35% and when included postoperative mortality 33% in both groups 
(p = 0.676).The presence of comorbidity was an independent prognostic factor for survival 
(p = 0.002).
Conclusions: Advanced age (≥ 70 years) has minor influence on postoperative course, 
recurrent disease and survival in patients who underwent an extended esophagectomy. 
Age alone is not a prognostic indicator for survival. We propose that a radical resection 










































Esophageal cancer predominantly occurs in the last decades of life, with a median age 
beyond 60 years.(1;2) Although important improvements have been achieved in the 
multimodality treatment of these tumors, surgery remains the primary curative option.
(3;4) Esophagectomy is a high risk procedure with serious postoperative complications 
and a reported mortality rate ranging from 2 to 6%.(1;3;5) Moreover, esophageal cancer 
patients often present considerable risk factors for major surgery, including obesity, pul-
monary and cardiovascular diseases. (6;7)
Besides the increasing incidence of esophageal adenocarcinoma, the rising life expectancy 
in the general population is responsible for a relatively large number of elderly patients 
with esophageal cancer.(1) Elderly patients who undergo esophagectomy often have a 
high prevalence of comorbidity and frailty, suggesting a negative effect on the outcome 
and postoperative course. (8-12) Therefore, surgeons are in general more reluctant to 
perform major surgery in these elderly patients.
There is a lack of evidence regarding the appropriate surgical treatment of esophageal 
cancer in the elderly population. Some authors propose a transhiatal procedure for bet-
ter short-term outcome with less morbidity, while others perform a standard extended 
esophagectomy with a two-field lymphadenectomy in all patients with esophageal car-
cinoma to achieve maximal oncologic control and minimizing the chance of recurrent 
disease.(13-15)
In absence of an established definition on elderly patients regarding high risk surgery, 
most studies defined advanced age as an age ≥ 70 years of age. (8;10;11;16-22)
We report the results from an experienced high volume single center, in elderly patients 
who underwent an extended transthoracic esophagectomy with a two field lymphadenec-
tomy for cancer of the esophagus. We performed several analyses to determine the effect 
of advanced age on comorbidity, postoperative course, recurrent disease and survival. 
We evaluated age as a selection criterion for surgery and make recommendations for the 
optimal treatment policy in elderly patients.
PatIentS anD methoDS
Patients characteristics and treatment
Between January 1991 and January 2007, 234 patients with cancer of the esophagus or 
gastroesophageal junction (GEJ) underwent esophagectomy with curative intent. All pa-
tients underwent surgery in the same high-volume university medical center by the same 










































to undergo surgery. Patients who underwent neo-adjuvant treatment in a nationwide 
trial, starting from 2006 on, were excluded for evaluation to prevent a treatment bias 
(n = 6). Patients who underwent exploration due to unforeseen extension of disease were 
excluded.
Comorbidity
Comorbidity was determined by The American Society of Anesthesiologists Physical Status 
(ASA) classification. ASA is a readily available and widely accepted way to stratify surgical 
patients according to their perioperative risk and varies between ASA 1 (very good condi-
tion) and ASA 5 (moribund patient).(23) ASA class was assigned by the anesthesiologist 
after completing a structured review of physical status just prior to the esophagectomy.
Preoperative workup
Patients were considered for curative esophagectomy after a complete preoperative 
workup which included: physical examination, standard laboratory tests, digestive en-
doscopy, histopathological examination of taken biopsies and detailed preoperative risk 
assessments. Staging of the tumors was performed by endoscopic ultrasonography (EUS) 
+ fine needle aspiration (FNA) and computed tomography (CT) of the chest, abdomen and 
cervical region. In all patients newly diagnosed T3-4 or N1 esophageal cancer a 18F-fluoro-
2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) was performed. In case of 
anatomical difficulties on PET assessment, a PET/CT fusion was performed. All patients 
were discussed preoperatively in multidisciplinary meetings.
Surgery
An extended esophageal resection was performed in all patients. This procedure consisted 
of a subtotal esophageal resection through a left thoraco-laparotomy with intrathoracic 
anastomoses for the distal and gastroesophageal cancers or through a right thoraco-mid 
laparotomy with cervical anastomoses for the higher intrathoracic tumors. Both were 
combined with a two-field lymphadenectomy of nodes at the celiac trunk, upper border 
of the pancreas, para-aortic region and mediastinal nodes.
histology
All resected specimens and lymph nodes were examined according to the standard proce-
dures. Tumor stage and grade were classified according to the sixth edition of the tumor-
node-metastasis system and the residual tumor (R) classification of the International Union 
Against Cancer and the American Joint Committee on Cancer. (24;25) Adenocarcinomas 











































Postoperative mortality was defined as any death within the first 90 days after operation 
and deaths within the same hospital admission. A separate calculation was made of only 
90 days mortality (without in hospital deaths after 90 days) to compare these figures with 
the data in literature. Major complications were divided into pulmonary complications: 
respiratory insufficiency (prolonged need for mechanical ventilation), acute respiratory 
distress syndrome (ARDS: acute and persistent lung inflammation with increased vascular 
permeability and severe hypoxemia), pneumonia (infiltrate on X-ray, sepsis and positive 
sputum culture, including bronchoaveolar lavage), atelectasis (collapse of lung lobe on 
X-ray with hypoxemia for which intensive physiotherapy or bronchoscopy was needed), 
pleural effusion (fluid seen on X-ray for which drainage was necessary because of hypox-
emia), empyema (positive culture or positive fluid) and pulmonary embolism (diagnosed 
on CT); Cardiac complications; arrhythmia (diagnosed on ECG) and myocardial infarction 
(diagnosed on ECG and positive laboratory tests); and other major complications; re-
bleeding (bleeding requiring transfusion or reoperation), subphrenic abscess and/or intra-
abdominal abscess (CT, drainage and positive culture), Systemic inflammatory response 
syndrome (SIRS: deregulated host with inflammatory response whit absent infection: 
temperature > 38.5 °C or < 35 °C, heart rate > 90 beats/min, respiratory rate > 20 breaths/
min or PaCO2 < 32 mmHg and white blood cells > 12,000 cells/mm3), sepsis (the clinical 
signs of SIRS, but with culture-proven infection or an infection identified by visual inspec-
tion), anastomotic leakage (CT with enteral contrast and amylase in the pleural fluid), 
chylothorax (chyle defined by measuring triglycerides), renal failure (rising creatinine and 
oliguria for which renal replacement therapy was necessary), liver failure (rising bilirubin, 
liver enzymes, lactate and prothrombin time), deep venous thrombosis (of the distal or 
proximal lower extremity) and ileus (absence of peristalsis with gastric retention and no 
defecation, confirmed with abdominal X-ray). Minor complications were defined as wound 
infections (positive wound culture with pus), wound dehiscence (spontaneous opening of 
the fascia) and urinary tract infections (UTI: sepsis, urinary leucocytes and 105 bacteria/
ml in the urine). Infectious complications were subdivided in septic complications (sepsis), 
intra-abdominal or subphrenic abscess eventually with anastomotic leakage, empyema, 
pneumonia, severe wound infections and urinary tract infections. The use of antibiotics 
and inotropes was scored during the postoperative period. The operation room (OR) time, 
intensive care unit (ICU) stay and hospital stay were measured for comparison.
follow-up
All medical follow-up data was collected prospectively, in a patient research database. Pa-
tients were seen in the outpatient department every 3 months for the first postoperative 










































patients was collected by consulting the general practitioners and the Comprehensive 
Cancer Center North Netherlands. Follow-up was measured in months from the time of 
operation until death (survival time) or end of follow-up with a minimum of two years.
For the calculation of long term cancer specific survival, patients without postoperative 
mortality were selected (n = 219) and only cancer related death cause was scored. Death 
of any other cause was scored as end of follow up. For all other survival calculations 
postoperative mortality was included into the survival curves.
Recurrent disease was defined as loco-regional recurrence or distant metastases in the 
follow-up period, determined by any cytologic or histologic proof, unequivocal radiologic 
suspicion (CT, MRI, PET, bone-scan and Ultrasonography) and/or obvious clinical manifes-
tations.
The follow-up was ascertained in February 2009, and complete for all included patients.
Definitions and Statistical analysis
For calculations ‘the elderly’ were defined as patient of 70 years of age and older, as 
generally used in literature. (8;10;11;16-22) Therefore, we discriminated between group I, 
< 70 years and group II, ≥ 70 years of age, independently of other factors.
Variables were reflected as frequencies with means and/or median with percentages. 
Continuous variables were compared by using the T-test and the Chi-Square test was used 
for comparison of categorical variables. Survival and recurrence rates were calculated by 
the Kaplan-Meier method and the log rank test. Survival calculations included postop-
erative mortality, except for the cancer specific survival. Prognostic factors for survival 
were calculated with Cox regression univariate and multivariate analyses. Univariate and 
multivariate logistic and linear regression analysis were used for calculating if advanced 
age was influencing the occurrence of comorbidity and complications; group of complica-
tions (cardiac, pulmonary and infectious complications) were calculated as well as the 
individual complications. Multivariate analysis was performed by incorporating factors as 
covariates with a p-value ≤ 0.1 on univariate analysis.
For all calculations a p-value of < 0.05 was considered to be significant. Statistical compu-
tations and figuring were all performed by using the statistical package SPSS version 16.0 
(SPSS Inc., Chicago, IL).
reSultS
Patient characteristics
The study population consisted of 234 consecutive patients; 196 males (84%) and 38 









































of age. Group I (< 70 years of age) consisted of 170 patients (73%) and group II (≥ 70 
years of age) of 64 patients (27%). Patients and tumor characteristics are summarized 
in table 1. Surgical characteristics such as year of surgery (p = 0.4) and type of resection 
(p = 0.9) were similar in both groups. Stage of disease was not statistically different in 
both groups (p = 0.148) although more advanced disease seems to occur in the younger 
patients (Table 1)
Comorbidity was not significantly different in both groups, respectively 65 patients (38%) 
with comorbidity in group I versus 32 patients (50%) in group II (p = 0.104). ASA scores did 
not differ between the two groups (p = 0.136).
mortality and comorbidity
Postoperative mortality (90 days and within hospital admission) was 6.2% (15 patients), 
8 patients (5%) in group I versus 7 patients (11%) in group II (p = 0.09). The 90 days 
mortality alone was 4,7% (11 patients), 5 patients (3%) in group I and 6 patients (9%) 






Mean age 58.9 74.5
Sex (M/F) 144/26 52/12 0.524 
histology
 Adenocarcinoma 145 (85) 56 (87)
 Squamous cell carcinoma 25 (15) 8 (13) 0.666 
localisation
 Midesophagus 14 (8) 4 (6)
 Distal esophagus 102 (60) 36 (56)  
 GEJ 54 (32) 24 (38) 0.371 
tumor stage
 I 17 (10) 11 (17)
 IIa 46 (27) 17 (26)  
 IIb 16 (9) 8 (13)  
 III 80 (47) 25 (39)  
 IVa 11 (7) 3 (5) 0.148 
Comorbidity
 Diabetes Mellitus 17 (10) 8 (13) 0.582
 Hypertension 28 (16) 15 (23) 0.221 
 Angina pectoris 12 (7) 5 (8) 0.843 
 Heart failure 1 (1) 2 (3) 0.125 
 Myocardial infarction 17 (10) 7 (11) 0.833 
 COPD 16 (9) 6 (9) 0.993 










































in group II (p = 0.08). Of the 15 patients who died postoperatively, 10 (67%) had more 
than one comorbidity (p = 0.041). Four patients had a history of myocardial infarction and 
hypertension; one patient had diabetes with myocardial infarction; two patients had dia-
betes with hypertension; one patient had chronic obstructive pulmonary disease (COPD) 
with transient ischemic attack (TIA), and two patients had a TIA with hypertension. Only 
cardiovascular comorbidity in the elderly subgroup (n = 24; 38%) had a negative effect on 
postoperative mortality (p = 0.043).
Complications
Ninety-nine patients (58%) in group I and 44 patients (69%) in group II developed 
postoperative complications, which was not statistically different between both groups 
(p = 0.142). Pulmonary complications occurred in 72 patients (42%) in group I versus 36 
patients (56%; p = 0.06) in group II, respectively. (Table 2) Respiratory insufficiency was the 
most frequent complication, and occurred more in the elderly patients (25% versus 41%; 
p = 0.017). Other major pulmonary complications atelectasis (14% vs. 28%; p = 0.009) 
and pleural effusion (15% vs. 27%; p = 0.036) occurred more frequent in group II. Cardiac 
complications, primarily consisting of arrhythmias, occurred in 27 patients (16%) versus 
24 patients (38%) in group II (p = 0.001). Pneumonia was the most common infectious 
complication in 43 patients (18%), 16% in group I and 23% in group II (p = 0.221). There 
were no differences between infectious and non-infectious complications between the 
two groups (p = 0.5). Four abscesses developed in the elderly group (6%).
The postoperative use of antibiotics and inotropes did not differ statistically between both 
age groups (p = 0.4 and p = 0.13).
In logistic regression analysis, age ≥ 70 years was no prognostic factor for develop-
ment of postoperative complications (Odd Ratio; OR = 1.578; 95% confidence interval; 
95%CI = 0.857 to 2.904; p = 0.143). For cardiac complications (OR = 3.178; 95%CI = 1.655 
to 6.100; p = 0.001) and pulmonary complications (OR = 1.750; 95%CI = 0.980 to 3.126; 
p = 0.05) as a group, age ≥ 70 years was a prognostic factor. (Table 3)
There was a higher rate of complications in the patients with comorbidity; 69 of the 97 
patients who had comorbidity (71%) developed one or multiple postoperative complica-
tions (p = 0.008). However, of the 143 patients who had complications only 69 (48%) had 
preoperative fixed comorbidity. In logistic regression analysis comorbidity was a prognos-
tic factor for developing postoperative complications (OR = 2.098, 95%CI = 1.207 to 3.647, 
p = 0.009)
Postoperative course
The operation time with a median of 6 hours was not different in both groups 









































64 days. In group II the ICU stay was significantly longer with a median of 7 days (range 1 
to 64 days) versus group I with a median of 3 days (range 1 to 56 days) (95%CI = −9.95 to 
−1.86; p = 0.005). Re-operation was needed in 29 patients due to complications, including 
anastomotic leakage, postoperative bleeding, subphrenic abscess and obstructive ileus 
based on torsion at the jejunostomy site. The median hospital stay was 22 days, with 21 
days in group I and 26 days in group II (95%CI = −11.03 to 0.17; p = 0.06).
table 2. Complications (n = 234)





overall complications 99 (58) 44 (69) 0.142
Pulmonary complications 72 (42) 36 (56) 0.058
 Respiratory insufficiency 42 (25) 26 (41) 0.017
 ARDS 4 (2) 3 (5) 0.351 
 Pneumonia 28 (16) 15 (23) 0.221 
 Atelectasis 23 (14) 18 (28) 0.009 
 Pleural effusion 25 (15) 17 (27) 0.036 
 Empyema 16 (9) 9 (14) 0.306 
 Pulmonary embolism 4 (2) 3 (5) 0.351 
Cardiac complications 27 (16) 24 (38) < 0.001
 Arrhythmia 27 (16) 23 (36) 0.001
 Myocardial infarction 2 (1) 1 (2) 0.815 
other major complications
 Rebleeding 4 (2) 4 (6) 0.144
 Subphrenic abcess 0 (0) 2 (3) 0.021 
 SIRS 3 (2) 4 (6) 0.073 
 Sepsis 14 (8) 9 (14) 0.183 
 Anastomotic leakage 31 (18) 8 (13) 0.295 
 Chylothorax 9 (5) 2 (3) 0.486 
 Intra-abdominal abces 0 (0) 2 (3) 0.021 
 Renal failure 8 (5) 5 (8) 0.356 
 Liver failure 0 (0) 1 (2) 0.103 
 Deep venous thromb 2 (1) 0 (0) 0.385 
 Ileus 2 (1) 2 (3 0.306 
minor complications
 Wound infection 9 (5) 9 (14) 0.025
 Wound dehiscence 3 (2) 2 (3) 0.522 
 Urinary tract infection 0 (0) 4 (6) 0.001 
Postoperative course
 Reoperation 17 (10) 12 (19) 0.064
 OR-time (mean hours) 6.1 6.3 0.384 
 ICU stay (mean days) 2.5 5.0 < 0.001 











































Median follow-up was 26 months (range 0–199 months) and no patients were lost to 
follow-up. Follow-up time was not different between the groups (p = 0.701).
Stage of disease had no impact on survival between the two groups (stage I, p = 0.298; 
stage II; p = 0.834; stage III; p = 0.184; stage IVa; p = 2.09).
None of the individual complications had a significant impact on survival. Overall, compli-
cations had no influence on both the long term survival including postoperative mortality 
(p = 0.174) and without mortality (p = 0.655).
table 3. Prognostic value of advanced age on development of complications; with group of complica-
tions (overall, pulmonary and cardiac complications) and individual complications. np = not enough 
statistical power.
variable odds ratio 95%CI P-value
overall complications 1.578 0.857 - 2.904 0.143
Pulmonary complications 1.750 0.980 - 3.126 0.050
 Respiratory insufficiency 2.085 1.135 - 3.832 0.018
 ARDS 2.041 0.444 - 9.383 0.359 
 Pneumonia 1.552 0.766 - 3.146 0.222 
 Atelectasis 2.501 1.242 - 5.037 0.010 
 Pleural effusion 2.098 1.043 - 4.218 0.038 
 Empyema 1.575 0.658 - 3.770 0.308 
 Pulmonary embolism 2.041 0.444 - 9.383 0.359 
Cardiac complications 3.178 1.655 - 6.100 0.001
 Arrhythmia 2.971 1.542 - 5.723 0.001
 Myocardial infarction 1.333 0.119 - 14.962 0.816 
other major complications
 Rebleeding 2.767 0.671 - 11.412 0.159
 Subphrenic abcess   np 
 SIRS 3.711 0.807 - 17.066 0.092 
 Sepsis 1.823 0.747 - 4.449 0.187 
 Anastomotic leakage 0.641 0.277 - 1.479 0.297 
 Chylothorax 0.577 0.121 - 2.746 0.490 
 Intra-abdominal abces   np 
 Renal failure 1.716 0.540 - 5.455 0.360 
 Liver failure   np 
 Deep venous thromb   np 
 Ileus 2.710 0.374 - 19.655 0.324 
minor complications
 Wound infection 2.927 1.106 - 7.748 0.031
 Wound dehiscence 1.796 0.293 - 11.003 0.527 









































Recurrent disease occurred in 126 patients (54%); 99 patients (58%) in group I and 27 
(42%) in group II (p = 0.028). Time to development of recurrent disease did not differ 
between the groups (p = 0.223).
For all 234 patients, including patients with postoperative mortality, the 1-year survival 
was 74% and the 5-year survival was 33%. There was no difference in survival between 
the two groups (p = 0.535), with a 1-year survival of 76% in group 1 versus 70% in group 
2 (p = 0.282) and a 5-year survival of 33% in group I versus 33% in group II (p = 0.676). 
(Figure 1)
Age classification in < 70 and ≥ 70 years of age did not have any prognostic value for 
survival (OR = 1.117, 95%CI = 0.787 to 1.584; p = 0.535). Also a rising age as continuous 
variable did not have a prognostic value for worse survival (OR = 1.005, 95%CI = 0.990 to 
1.021; p = 0.514).
 figure 1. Kaplan Meier overall survival curve (n = 234) of patients in group I, < 70 years and group II, 











































figure 2a. Kaplan Meier survival curve of patients in group I (< 70 years) with preoperative comorbid-
ity and those without (n = 65 versus n = 105, p = 0.472).
 
figure 2B. Kaplan Meier survival curve of patients in group II (≥ 70 years) with preoperative comorbid-









































Cancer related 5-year survival, in patients without postoperative mortality (n = 219) and 
cancer related cause of death, was 35% and did not differ between the groups (35% versus 
37%, p = 0.874).
Survival curves of comorbidity versus age showed no difference between the two groups 
(p = 0.135). In group I and II separately, there was no statistical difference in survival of 
patients with and without comorbidity. (Figure 2A and 2B) Although there was a trend for 
worse survival in elderly patients with comorbidity (p = 0.087). (Figure 2B)
The presence of comorbidity was an independent prognostic factor for long term survival 
(OR = 1.679 95%CI = 1.219 to 2.314; p = 0.002. The Kaplan Meier curve showed significant 
better survival for patients without comorbidity in the long term (p = 0.001). (Figure 3).
 
 figure 3. Kaplan Meier survival curve of patients with preoperative comorbidity and those without, 











































By applying a thoracotomy-based operative approach with extensive 2-field lymph node 
dissection for esophageal cancer, we were able to effectuate a 5-year cancer specific 
survival rate of 35% in a patient population with 49% stage III and IV disease, regardless 
of age and comorbidity.
The median hospital stay was comparable with reported numbers in literature. (12) Hos-
pital stay is relative long because some patients with comorbidity in this relatively high-
aged population needed extensive pre-operative workup. Moreover, in our hospital most 
patients with anastomotic leakage are usually treated conservatively with good results.
Advanced age (≥ 70 years) had no significant influence on mortality following extended 
esophagectomy, even though there was a non-statistical trend of a higher postoperative 
mortality. Overall, elderly patients had no higher postoperative complication rate than 
the younger group. However, cardiac complications in particular arrhythmia, and pulmo-
nary complications, especially respiratory insufficiency, atelectasis and pleural effusion, 
occurred more frequently in the elderly patients. Age ≥ 70 years was not a prognostic 
factor for development of postoperative complications. Furthermore, the occurrence 
of complications did not lead to a decreased survival. On the other hand comorbidity 
was the strongest prognostic factor for the development of complications. In this study 
cardiovascular comorbidity in the elderly subgroup had a negative effect on postoperative 
mortality. Because of this relatively small sized subgroup, it is difficult to give specific 
recommendations.
Compared with patients < 70 years recurrent disease was significant lower in the elderly 
group. But the higher number of cardiopulmonary complications and the trend for a higher 
postoperative mortality in the elderly is concerning.
Along with a general rise of incidence of esophageal adenocarcinoma, there is a rising 
incidence in esophageal cancer in the elderly patients up to 600% in the last decades.(26) 
Advances in treatment of esophageal cancer surgery have been remarkable; improved 
staging modalities, perioperative management, surgical techniques and postoperative 
care have reduced postoperative mortality and morbidity rates and enhanced better sur-
vival. Moreover, improvements in postoperative complications in the elderly are reported.
(19)
Our results reflect the improvement in overall outcomes following esophagectomy for 
cancer over the last ten years and demonstrate that this improvement in short-term out-
come is evident in the elderly population.(20) Several studies reported worse postopera-
tive course in the elderly patients, with a high mortality rate and a decreased overall long 
term survival with increasing age.(20;22) More recent studies showed acceptable results 









































more intensive perioperative care.(8;10-12;16-19;21;27) Therefore, some studies focus 
on even older patients (> 75 or > 80 years). (9;12;16).
Preoperative risk assessment and estimation of prognostic risk factors in the elderly remain 
controversial. Some studies found a strong association between high age and increased 
risk of worse prognosis during and after esophagectomy.(7;28) Particularly cardiac and 
pulmonary complications occur more frequently in the high age groups.(8;16;19;28) How-
ever, reliable individual risk analysis stratification for individual elderly patients is lacking. 
This is mainly due to a reluctance to enroll elderly patients in clinical trials, which we think 
is not appropriate.(29) This is of importance, because the elderly have more cardiopulmo-
nary complications which complicate the postoperative course. More research is needed 
for adequate scoring systems identifying the elderly at risk for pulmonary and cardiac 
complications.(8;16;19;28) This may permit preoperative intervention such as cardiac and 
pulmonary support which can reduce the risk of postoperative complications.(12)
In the literature, a discussion is ongoing on the type of surgery required for elderly pa-
tients. Some surgeons advocate a limited resection due to postoperative complications 
and co-existing disease in the elderly. However, transthoracic esophagectomy with two-
field lymph node dissection is not associated with increased mortality or reduced long 
term survival in the elderly population.(20) In this study there was a higher mortality 
rate in the elderly, although not significant, but elderly patients had an equally long term 
survival after surgery. Further optimization in selection criteria and risk stratification for 
the elderly will better clarify the supposed advantage of extended esophagectomy. Hence 
we recommend thorough preoperative assessment in all patients. A threshold to deny 
surgery based only on age seems not reasonable in this patient group, because of large 
differences in comorbidity and clinical manifestations of cancer.
A larger study group might strengthen the non-statistical trends on postoperative mortal-
ity in this study, suggesting the need for a large prospective study. The choice to oper-
ate on elderly patients with comorbidity remains difficult, but the consequences to not 
operate is even a greater dilemma. The strength of this study is the careful selection of 
patients for surgery, the homogeneous groups for comparison and the complete follow 
up. It quantifies what the risk is in an experienced center.
More attention is needed in prospective clinical trials for elderly patients, further improving 
postoperative course and long term survival. Furthermore, individual risk analysis stratifi-
cation should be developed with a focus on patients with comorbidity. Centralization and 
more intensive perioperative care for elderly patients are mandatory. Our data support 
the view that esophageal resection within centralized organized care with a coordinated 
multidisciplinary approach and multidisciplinary teamwork is feasible and appropriate for 
all reasonably fit patients, regardless of age. The increased use of neo-adjuvant therapy 










































individualization of treatment will be the future standard. A subdivision based solely on 
age is undesirable. Elderly patients with no preoperative risk factors may be more readily 
tolerate chemo-radiotherapy and surgery than younger patients with comorbidity.
In conclusion, the increasing life expectancy in the general population will lead to a fur-
ther increasing incidence of elderly patients with esophageal cancer in the near future. 
Therefore more attention is needed for the treatment of the elderly patients. As this study 
showed no significant difference in short and long term survival for the elderly group, and 
elderly patients had no substantial worse postoperative course, a radical resection should 
not be withheld in the elderly patients. Although, age alone is not a prognostic indicator 
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Background: Different risk-prediction models have been developed, but none is gener-
ally accepted in selecting patients for esophagectomy. This study evaluated five most 
frequently used risk-prediction models, including the American Society of Anaesthesiolo-
gists (ASA), P-POSSUM, O-POSSUM, Charlson and its age adjusted score (ACCI) to asses 
postoperative mortality after transthoracic esophagectomy.
methods: Data were obtained from 278 consecutive esophageal cancer patients between 
1991 and 2007. Performance in predicting postoperative mortality (in-hospital and 90-day 
mortality), were analyzed regarding calibration (Hosmer and Lemeshow goodness-of-fit 
(HLG) test) and discrimination (area under the Receiver Operator Curve (ROC)).
results: The HLG test was applied to each model and showed a significant outcome for 
only the P-POSSUM score (p = 0.035). The ROC curve indicated discriminatory power for 
P-POSSUM (0.766) and for O-POSSUM (0.756) other models didn’t exceed the minimal 
surface of 0.7.
Conclusion: Postoperative mortality after esophagectomy was best predicted by O-










































Esophageal cancer is associated with high rates of perioperative morbidity and mortality 
and a relatively low overall 5-year survival rate of approximately 25% [1]. The incidence 
is increasing rapidly and appears to be most prominent in vulnerable and fragile elderly 
of > 70 years who withstand major surgical insult as well[2]. Unfortunately, many elderly 
patients have serious comorbidities interfering with the outcome of treatment [3,4]. 
Careful preoperative assessment of fitness and subsequent selection of appropriate surgi-
cal candidates are important steps improving short-term outcome for individuals who 
undergo an esophagectomy.
New standard treatment methods, including neo-adjuvant chemoradiotherapy with re-
ported complete responses of 20-40% after resection, can be performed safely in a great 
part of these patients[5]. Nevertheless, surgery remains the primary curative option[6,7]. 
However, esophagectomy as a high-risk complex surgical procedure has a severe postop-
erative complication rate of up to 50% with a relatively high postoperative mortality of 
around 5% and in some cohorts even approaching 10-15% [6,8,9].
Preoperative risk stratification for postoperative mortality may help patients and families 
address the magnitude of both the disease and the therapy. It is pivotal for both the pa-
tient and the surgeon to realistically assess the magnitude of the surgical insult. Therefore 
we propose to assess several preoperative scoring systems that have each been validated 
as predictive of severe postoperative morbidity and mortality[10-14].
These “risk stratification/adjustment systems” include the “Physiological and Operative 
Severity Score for the enUmeration of Mortality and morbidity” (POSSUM), its Portsmouth 
(P-POSSUM) and O-POSSUM modifications, the Charlson Comorbidity Index (CCI) with the 
version of Age Adjusted Charlson Score (ACCI) and the standard American Society of Anes-
thesiologists (ASA) classification systems. In most of these systems age is not included as a 
dominant predictor of morbidity that is uniquely relevant to esophageal cancer presenting 
nowadays in more aging patients.[14]. Until now there are no published studies compar-
ing all these five comorbidity models (P- and O-POSSUM, Charlson-, ACCI- and ASA score) 
for patients after esophagectomy. We examined which of these five most frequently used 
comorbidity models could predict short-term surgical outcomes accurately following 












































Between January 1991 and December 2007, 280 consecutive patients with cancer of the 
esophagus underwent a surgical resection with curative intent. Two patients with missing 
follow-up were excluded from the analysis. In the remaining group of 278 patients analy-
sis was performed based on prospectively registered data from a computerized database 
of all esophageal procedures at our university hospital. (Table 1) Data of this study were 
evaluated according to the rules of ethical board of our institute. There were no systemic 
changes over the study period in the methods of acquiring patient comorbidity data.
Preoperative work up
Preoperative evaluation consisted of physical examination, standard laboratory tests 
and detailed preoperative risk assessments. Staging was performed by endoscopic 
ultrasonography (EUS) with fine needle aspiration (FNA) of suspected lesions and 16-64 
slice multidetector computed tomography (MDCT) of the chest, abdomen and cervical 
region. From 1996 on all patients diagnosed as T3-4 or N1 were additionally staged 
with 18F-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) and PET/CT 
fusion was applied in case of anatomical difficulties on PET assessment. Since 2007 neo-
adjuvant chemoradiotherapy consisting of paclitaxel 50mg/m2 and carboplatin (AUC = 2) 
on day 1,8,15,22 and 29 with concurrent radiotherapy of 41.4 Gy (23 fractions of 1.8 Gy), 
was administered to ten patients, as a part of a randomized control trial with surgery 
alone.
Surgery
Surgery in our tertiary referral centre was performed by two experienced surgeons. 
All patients underwent a curative intended open radical transthoracic esophagectomy 
consisting of a subtotal esophageal resection including a two-field lymphadenectomy of 
nodes at the celiac trunk, along the upper border of the pancreas, para-aortic region and 
mediastinal nodes. Pathological staging was based according to the latest edition of the 
TNM classification for esophageal cancer[15].
Comorbidity and mortality indexes
Overall comorbidity severity was classified according to the modified Physiological and 
Operative Severity Score for the enUmeration of Mortality and morbidity (P-POSSUM and 
O-POSSUM), Charlson-, Age Adjusted Charlson- and ASA score.
The original POSSUM score overpredicted mortality in low-risk patients[16] and therefore 









































regression. Both risk prediction models are based on a preoperatively available 12-fac-
tor physiological score and a 6-factor operative severity score obtained after surgery. To 
provide in the need for a specialized risk prediction model for esophagogastric surgery, 
the adapted O-POSSUM equation was designed[17] (Table 1).
The nineteen conditions of the Charlson comorbidity index (CCI) were found to sig-
nificantly influence survival and were given a weighted, risk-adjusted comorbidity index 
value, varying from 1 to 6 points, for the individual patient[18]. Patients with a low score 
were considered to have minimal co-morbid diseases in their medical history. In our study 
we used the modification by Romano et al[19], as it excludes cancer diagnosis in deter-
mining comorbidity and is commonly used in cancer outcomes research. The Charlson 
comorbidity index reflects both the number and gravity of co-morbid diseases. Besides 
the Charlson score, we also used the Age Adjusted Charlson Index (ACCI) scorings system, 
which characterized the impact of age and comorbidity on disease progression and sur-
vival after surgery[20]. Both models were initially developed for administrative databases 
and not for individual patient level data sets. The commonly used American Society of 
Anesthesiologists Physical Status (ASA) classification is a readily available and widely ac-
cepted to stratify surgical patients according to their perioperative risk. It varies from ASA 
1 (normal healthy patient in good condition) to ASA 5 (moribund patient, not expected 
to survive) [21]. ASA class is assigned by the attending anaesthesiologist after complet-
ing a structured review of physical status just prior to the patient’s surgical procedure. 
Although the ASA classification was initially not intended to predict survival beyond the 
perioperative period, several investigators demonstrated a prognostic value for the ASA 
classification beyond this period[21].
table 1. Variables of P-POSSUM and O-POSSUM
Physiological score operative severity score
Age (years) Operative severity
Glasgow coma score Multiple procedures
Cardiac signs Total blood loss *
Respiratory signs Peritoneal soiling *
Electrocardiography Presence of malignancy *
Systolic pressure (mmHg) Mode of surgery
Pulse rate (beats/min)
Haemoglobin (g/dl)















































The primary outcome was postoperative mortality, hereby defined as death within 90 days 
after esophagectomy or any death during admission in hospital where the resection was 
performed. This time period was applied to include all operation-related deceased pa-
tients. The observed number of deceased patients was divided by the number of expected 
deceased patients (O/E) and gave a standard mortality ratio (SMR). The performance of 
P- and O-POSSUM, Charlson-, ACCI- and the ASA score in predicting postoperative mortal-
ity was analysed regarding calibration and discrimination. Calibration refers to the agree-
ment between observed outcomes and predicted probabilities and concerns the expected 
mortality rate for a group of patients. Comparison between observed and expected (O-E) 
deaths for each model was analysed with the Hosmer and Lemeshow (HL) goodness-of-fit 
test. [22,23] Higher values of the HL statistic represent poorer model calibration. In this 
analysis a value of P < 0.05 was considered to show a statistically significant lack of fit. 
Discrimination refers to the ability to distinguish patients who will die from those who will 
survive by computing the area under the receiver operating characteristic (ROC) curve 
(AUC). Values between 0.7-0.8 suggest reasonable or moderate discrimination and values 
exceeding 0.8 suggest good or excellent discrimination.
For a better applicability in clinical practice, both POSSUM models were divided into three 
risk categories: group I (low risk) with a postoperative mortality rate: 0 – < 8%; group II 
(intermediate risk): 8 – < 15% and group III (high risk): ≥ 15 – 100% [24].
To counteract the possibility of changes in hidden care over the study period (1991-2007) 
of time we divided this period in three segments. The predictive powers of these models 
were analyzed in each time segment and were compared with the overall predictive 
power. All statistical analyses were conducted by the statistical software SPSS 16.0.2 (SPSS 
Inc., Chicago IL, USA).
reSultS
Clinicopathologic characteristics of the patients are summarized in Table 2. The 90-day 
postoperative mortality was 6.5% (18 patients), including an in-hospital mortality of 5.4% 
(n = 15). The overall comorbidity severity evaluated according to the five most commonly 
used models was as follows.
evaluation of the PoSSum equation
The expected mortality ratio by P-POSSUM was 6.2% (17 patients) giving a standardized 
mortality ratio (SMR) of 1.05 (18/17). O-POSSUM expected a postoperative mortality rate 









































value indicates an overestimation by O-POSSUM. The risk classification of both POSSUM 
models, with subdivision in observed (O) and expected (E) mortality rates, are summa-
rized by Table 3.
Calibration of the Hosmer and Lemeshow statistic demonstrated no fit to the observed 
data for P-POSSUM (χ2 = 16.580, 8df (degrees of freedom), p = 0.035), in contrast to the 
calibration of O-POSSUM (χ2 = 7.074, 8df, p = 0.529; Table 4). The area under the ROC 
curve for P-POSSUM was 0.766 (95% confidence interval (C.I) 0.67 to 0.86; p = 0.000), 
table 2. Patient (N = 278) and tumor characteristics according to postoperative outcome.
Postoperative survivors 
(n = 260) (%)
Postoperative deceased patients 
(n = 18) (%)
Median age (years) (range) 63 (29-85) 70 (55-81)
Sex (M/F) 214 / 46 (82.3/17.7) 15 / 3 (83.3/16.7)
histology
Adenocarcinoma 218 (83.9) 17 (94.4)
Squamous cell carcinoma 42 (16.2) 1 (5.6)
localization
Midesophageal 22 (8.5) 1 (5.5)
Distal esophagus 238 (91.5) 16 (94.5)
tumor stage
I 38 (14.7) 1 (5.6)
IIa 68 (26.2) 2 (11.1)
IIb 34 (13.1) 0 (0.0)
III 107 (41.2) 14 (77.8)
Iva 13 (5.0) 1 (5.6)




Patients (N) Observed mortality % (N) Expected mortality % (N)
0 – < 8 219 3.7% (8) 3.5% (8)
8 – < 15 41 12.2% (5) 10.6% (4)
≥ 15 – 100 18 27.8% (5) 29.1% (5)
Total 278 6.5% (18) 6.2% (17)
o-PoSSum
Score (%)*
0 – < 8 137 1.5% (2) 4.8% (7)
8 – < 15 97 9.3% (9) 11.4% (11)
≥ 15 – 100 44 15.9% (7) 20.8% (9)











































indicating discriminatory power for postoperative mortality. A similar result was found 
for O-POSSUM, ROC curve analysis revealed discriminatory capability for postoperative 
deaths with an AUC of 0.756 (95% CI: 0.67 to 0.84; p = 0.000).
evaluation of the Charlson and aCCI score
In our cohort the Charlson score ranged from 0 to a maximum of 4 points. Patients with a 
Charlson score of 0 points had an observed postoperative mortality of 5.6% (8 patients), 
score of 1 point: 4.9% (4 patients), score of 2 points: 11.4% (4 patients), score of 3 points: 
12.5% (2 patients) and none with a score of 4 points (Table 5). The Age Adjusted Charlson 






ROC curve (95% CI)
P-POSSUM 0.035 0.766 (0.67 – 0.86)
O-POSSUM 0.529 0.756 (0.67 – 0.84)
Charlson score 0.659 0.567 (0.42 – 0.71)
ACCI score 0.270 0.684 (0.58 – 0.79)
ASA score 0.210 0.635 (0.51 – 0.76)
table 5. Outcomes of Charlson, ACCI and ASA score
Charlson score Patients (N) Observed mortality (%) (N)
0 143 5.6% (8)
1 82 4.9% (4)
2 35 11.4% (4)
3 16 12.5% (2)
4 2 0.0% (0)
ACCI score
0 20 0.0% (0)
1 55 0.0% (0)
2 64 7.8% (5)
3 71 7.0% (5)
4 39 12.8% (5)
5 15 0.0% (0)
6 12 25.0% (3)
7 2 0.0% (0)
ASA score
1 36 0.0% (0)
2 177 6.2% (11)
3 60 8.3% (5)









































score in the study group ranged from 0 to 7 points and showed similar postoperative 
mortality rates; with in general increased risk of mortality with higher scores (Table 5).
The Hosmer and Lemeshow goodness of fit test, when applied to the Charlson score, 
indicated a good fit to the observed postoperative deaths (χ2 = 0.833, 2df, p = 0.659), 
as well as the ACCI score, which showed a similar fit to the observed data (χ2 = 5.174, 
4df, p = 0.270; Table 4). The area under the ROC curve for the Charlson score was 0.567 
(95% CI: 0.42-0.71; p = 0.344) indicating no discriminatory power. Similar results were 
found regarding the area under the ROC curve for the ACCI score, there was a same poor 
discriminatory power; 0.684 (95% CI: 0.58-0.79; p = 0.009). Since neither of the models 
showed a good fit with the observed data, they were not divided into risk categories.
evaluation of the aSa score
There was no postoperative death in the group of patients with an ASA score 1. Patients 
with an ASA score of 2 had an observed postoperative mortality rate of 6.2% (11 patients) 
and in the subsequent ASA 3 score, five deceased patients (8.3%) were observed. In the 
highest ASA score 4, the observed mortality increased to 40.0% (two patients; Table 5).
Using the Hosmer and Lemeshow goodness-of-fit test, no significant difference could be 
found between the observed and expected frequencies in the ASA classification (χ2 = 1.570 
1df, p = 0.210; Table 4). The area under the ROC curve (0.635, 95% CI: 0.51-0.76; p = 0.055) 
did not indicate a discriminatory power. Therefore, the ASA score was not divided into risk 
categories.
Specification of mortality incidence during the time period
To identify possible differences related to changes in practice over the time, the study 
time (1991-2007) was divided in three 5-year segments. The 90-day mortality rate was 
not significantly different compared to the overall mortality of 6.5%: i.e 5.8% from 1991-
1996 (p = 0.854), 8.8% from 1997-2002 (p = 0.396) and 5.7% from 2003-2007 (p = 0.721). 
However, a significant part of the patients who deceased postoperatively had one or more 
severe comorbidity (p = 0.018). Of cardiovascular disease which occurred frequently, 
TIA/CVA (p = 0.007) was observed significantly more during 1991-1996, hypertension 
(p = 0.019) more between 1997-2002 and angina pectoris (p = 0.000) more between 
2003-2007 (Table 6). Additionally, the predictive power of each model did not differ in 
these three time periods and both POSSUM models had the strongest predictive power 











































Risk stratification in high-risk cancer surgery is pivotal in identifying patients who may 
benefit from specific perioperative management strategies. Although it is difficult to 
define risk factors associated with adverse outcome in individual patients, evaluation of 
postoperative mortality and morbidity is not only necessary for adequate preoperative 
selection of patients but also for a reliable auditing process comparing outcomes across 
surgeons and hospitals. In the present study from a single tertiary-care referral center, 
statistical analyses demonstrated the most accurate individual risk probabilities for O-
POSSUM. Overall postoperative mortality was well predicted by the P-POSSUM equation 
with a low rate of underprediction (N = 1). Therefore, in our cohort the P-POSSUM equa-
tion is the most powerful predictor when comparing different cohorts.
There seems to be a contradiction between the overestimated value of postoperative 
mortality by O-POSSUM and its accurate calibration and discriminatory power for an 
individual patient. However, predictive accuracy refers to the ability of a model to assign 
the correct probability of death to patients, whereas discriminatory power refers to the 
ability of a model to attribute the correct outcomes to patients[24].
External validation showed varied results regarding prognostic values for these risk-
prediction models [11-13, 21-27]. Two studies, which compared the P-POSSUM and O-
POSSUM equation, demonstrated a poor HLG of fit for O-POSSUM, while one suggested 
good predictive power for P-POSSUM [25,26]. Several studies evaluated the O-POSSUM 
table 6. Survival and comorbidity rates in patients during three time periods
Postoperative survivors in periods (%) Postoperative deceased patients in 
periods (%)
overall 91-96 97-02 03-07 overall 91-96 97-02 03-07
90-day mortality 260 (93.5) 81 (94.2) 62 (91.2) 119 (94.4) 18 (6.5) 5 (5.8) 6 (8.8) 7 (5.6)
Comorbidity
Yes/No 114/146 24/57 27/35 63/56 13/5 2/3 4/2 7/0
Diabetes Mellitus 28 (10.8) 5 (6.2) 8 (12.9) 15 (12.6) 3 (16.7) 1 (20.0) 2 (33.3) 0 (0.0)
Hypertension 52 (20.0) 7 (8.6) 8 (12.9) 37 (31.1) 5 (27.8) 0 (0.0) 3 (50.0) 2 (28.6)
COPD 33 (12.7) 4 (4.9) 8 (12.9) 21 (17.6) 1 (5.6) 0 (0.0) 0 (0.0) 1 (14.3)
Angina pectoris 33 (12.7) 11 (13.6) 4 (6.5) 3 (2.5) 3 (16.7) 0 (0.0) 0 (0.0) 3 (42.9)
Congestive heart failure 3 (1.2) 0 (0.0) 0 (0.0) 3 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
myocardial infarction
TIA/CVA 28 (10.8) 10 (12.3) 4 (6.5) 14 (11.8) 3 (16.7) 1 (20.0) 0 (0.0) 2 (28.6)
14 (5.4) 1 (1.2) 3 (4.8) 10 (8.4) 2 (11.1) 1 (20.0) 0 (0.0) 1 (14.3)
COPD: Chronic Obstructive Pulmonary Disease









































equation and found a variety of results ranging from moderate to good fit [13,24]. Only 
a few studies were performed to validated the predictive power of Charlson-, ACCI-, and 
ASA score after esophagectomy [11,12]. In a recent study, an association has been sug-
gested between a high Charlson score (> 2) and mortality [11], two other studies indicated 
a relationship between mortality and ASA score [12,21].
These varied results may have several causes. In the first place, these risk-adjusted mod-
els could be interpreted in various ways by investigators. For example, the ASA score is 
defined by an individual anaesthetist at a specific moment and assessments might be 
influenced by variations in the clinical presentation. Moreover, the ASA score is interob-
server dependent and prone to allocation variation.
A second important difference lies in the definition of mortality. The majority of the 
conducted studies used 30-day mortality as a determinant of surgical outcome, while 
others used in-hospital mortality. In the present study we used the overall postoperative 
mortality, defined as in-hospital and 90-day mortality. Most of the applied risk predic-
tion models are developed to calculate mortality risk, without any corrections regarding 
post-admission death within a reasonable period. In applying the 90-day mortality, we 
included all operation-related deceased patients. None of these patients deceased on 
other circumstances rather than on the impact of the surgery. As many patients have a 
predictable short life span we have to rethink the value of a therapeutic strategy, if much 
time was spent to recuperate from major surgical stress.
Thirdly, since hospital volume appeared to be an import prognostic value [6], it would be 
difficult to identify predictive risk factors, particularly in an heterogeneous group. There-
fore, we only examined patients who underwent a uniform surgical approach, including a 
transthoracic esophagectomy with a 2-field lymphadenectomy in a tertiary referral centre 
with a high hospital and surgeon volume. Although still prematurely, recent literature 
showed a decrease in severity and frequency of morbidity in patients who underwent a 
laparoscopic approach, but evidence for a reduced mortality has not been established 
yet [27,28]. None of the patients in this study had a laparoscopic approach and further 
research is necessary to examine the applicability of these risk prediction models in such 
a cohort.
A drawback of this study lies in the time span of 16 years. A number of factors affecting 
survival may have evolved over this period of time such as better patient selection or 
newer technology, including neoadjuvant chemoradiation and surgical approaches. To 
counteract the possibility of interfering factors over this period, we divided the time span 
in three almost equal segments. Mortality rates didn’t differ significantly over this period 
and statistical analysis indicated the most predictive power for both POSSUM models in 
each segment. The influence of neoadjuvant chemoradiation in this study was low as 










































Recently, new risk-adjusted models were developed, including the Rotterdam-, Phila-
delphia- and Munich score to compare cohorts, but they do not provide individual risk 
stratification as was clearly concluded by Zingg et al [29].
So far a reliable individual risk analysis stratification to guide surgeons and oncologists in 
the decision-making is missing and it should be done in the context of an overall clinical 
judgment. With a more appropriate risk-prediction model, we might be able to identify 
patients with high estimated morbidity and mortality. A careful selection based on such 
models may be helpful to perform adequate preoperative interventions and reducing the 
risk of postoperative complications.
Current centralization of this high-risk surgery has led to a relatively low postoperative 
morbidity and better outcome has been observed in high-volume centers for moderate- to 
high-risk patients. [30] Predicting the mortality risk in an individual patient is difficult. The 
number of events is too few to justify clinical application of any scoring system without 
further validation with prospective data in the setting of a clinical trial. To counteract 
the impossibility of the current models in selecting the individual at-risk patient, we 
subdivided the most accurate model into a low, intermediate and high-risk category. The 
benefit of this subdivision for a model is no longer the identification of a rare event, but to 
identify a group of patients with an increased mortality risk. Thereby, it would be a benefit 
for the informed consent and usefulness of a model; since it is immediately obvious to 
which risk group a patient belongs. To justify this distribution in clinical practice, more 
research is necessary to validate this quantification.
ConCluSIon
Each risk-adjusted model demonstrated a moderate relationship between postoperative 
mortality and an increased risk score. We recommend the O-POSSUM for individual risk 
stratification as it assessed the condition of the patient and the risk of surgery most ac-
curately in this study. In clinical practice we suggest dividing the O-POSSUM score into a 
low, intermediate and high-risk category, but before general application more research is 
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Background: Neoadjuvant chemoradiotherapy (CRT) in esophageal cancer (EC) patients 
may increase the formation of thromboembolic events (TEE’s). We analyzed the incidence 
and impact of TEE’s in EC patients treated with platinum-based CRT.
Patient and methods: A total of 336 patients with EC underwent an esophagectomy of 
which 110 patients received neoadjuvant CRT (41.4Gy with concurrent Carboplatin/Pacli-
taxel). Patients were matched based on pre- and perioperative characteristics.
results: Preoperatively, 9 (8.2%) patients with neoadjuvant CRT (p = 0.004) were diag-
nosed with TEE’s. Despite delay until surgery (p = 0.021), the postoperative course did 
not differ. In multivariate analysis, a history of DVT (p = 0.005) and neoadjuvant CRT 
(p = 0.004) were identified as risk factors. Postoperatively, there was no differences in 
TEE’s (p = 0.560) observed. In multivariate analysis, a history of pulmonary embolism 
(p = 0.012) was identified as risk factor for postoperative TEE’s.
Conclusion: Preoperatively, EC patients treated with neoadjuvant CRT have an increased 
risk to develop a TEE, especially those with a previous history of TEE. After surgery no 
increased incidence was observed. We recommend secondary prophylaxis during neoad-










































Neoadjuvant chemoradiotherapy (CRT) followed by surgical resection is a widely accepted 
curative intended treatment in patients with esophageal cancer (EC). Depending on onco-
logical and conditional criteria, patients receive in our center radiotherapy (41.4Gy/5wks) 
and concurrent chemotherapy (Carboplatin and Paclitaxel) according to the CROSS regi-
men. This platinum-based neoadjuvant CRT improves loco-regional control and overall 
survival with 13% at 5 years(1).
As distinct from this benefit, neoadjuvant CRT may subsequently be accompanied by an 
increased risk for adverse pre- and postoperative complications(2). It is known that cancer 
patients, especially those with gastro-esophageal cancer, generally have a high risk of 
venous thrombosis(3, 4). Moreover, the use of chemoradiotherapy seems to be associ-
ated with a further enhanced risk of developing thromboembolic events (TEE’s), including 
deep vein thrombosis (DVT) and pulmonary embolism (PE)(5-9).
In the mid-nineteenth century Virchow and Trousseau described the pathophysiology of 
TEE’s in cancer patients. However, there still exist significant gaps in the understanding 
of cancer-associated TEE’s in patients treated with chemotherapy alone or combined 
with radiotherapy. Reported incidences of TEE’s during chemotherapy for EC are ap-
proximately 10 to 12%, and partly depending on the type of chemotherapy(9). The risk 
of TEE’s in currently used neoadjuvant CROSS regimen is, according to our knowledge, 
not previously described. The hypothesis in the present study was that neoadjuvant 




In this study, we included all 336 patients who underwent a transthoracic esophagectomy 
with curative intent between January 2000 and December 2012. Of these patients 110 
(32.7%) received neoadjuvant CRT followed by surgery between January 2006 and De-
cember 2012. Patients with unforeseen progression of their disease were excluded (N = 5). 
All data was collected prospectively, including: demographic and tumor characteristics, 
comorbidity, therapeutic information, details about neoadjuvant treatment, medication, 
pre- and postoperative complications, and survival data.
To reduce bias in selection criteria and interfering factors in developing TEE’s, we created 
statistically comparable groups by propensity matching. The propensity score is used 










































be appreciably similar in observed dimensions (implemented in our SPSS package(10)). 
Patients treated with neoadjuvant CRT (N = 110) were matched with 95 patients who 
were treated between 2000 and 2012 with surgery alone. Patients were matched for: 
sex, medical history of deep venous thrombosis (DVT), pulmonary embolism, myocardial 
infarction, and TIA/CVA, ASA classification, and preoperative cTstage.
neoadjuvant chemoradiotherapy
Patients who were eligible for neoadjuvant CRT received Carboplatin, which was adminis-
tered weekly with a targeted area under the curve (AUC) of 2 mg per milliliter per minute 
and Paclitaxel of 50 mg/m2 for 5 weeks. Concurrent radiotherapy, which consisted of 
41·4 Gy in 23 fractions of 1·8 Gy, was administered five times per week. Radiotherapy 
target volumes were delineated on a planning computed tomography (CT) scan by an 
experienced radiation oncologist. Oncologic criteria consisted of a clinical tumor stage of 
T1N1-3 or T2-T4aN0-3 without distant metastases (M0). Conditional requirements were 
based on the judgment of the surgeon and both the medical and radiation oncologist and 
were comparable to the eligibility criteria of the national CROSS study(1).
Preoperative evaluation and comorbidity
All patients were staged with an endoscopic ultrasonography (EUS) including fine needle 
aspiration (FNA) and 16-64 slice spiral multidetector computed tomography (MDCT) 
with intravenous and oral contrast of the neck, chest, and abdomen. In locally advanced 
tumors (T3-4a or N1-3), an 18F-fluoro-2-deoxy-D-glucose Positron Emission Tomography 
(FDG-PET) was performed. For the final analysis, the available reports of every EC patient 
were reviewed and discussed in a multidisciplinary tumor specific board to assess ap-
propriate management. Patients treated with surgery alone underwent an esophageal 
resection within 4-8 weeks after staging. In patients treated with neoadjuvant CRT, a re-
staging MDCT with intravenous contrast of the neck, chest, and abdomen was performed 
to exclude progressive disease in assessing resectability.
Comorbidity was classified according to the American Society of Anesthesiology (ASA) 
score varying from ASA 1 (very good condition) to ASA 5 (moribund patient). The ASA 
score is a readily available and widely accepted method to stratify surgical patients ac-
cording to their pre-operative risk.
Surgery
All patients underwent, usually within 4-8 weeks after (re)staging, a transthoracic 
esophagectomy with two-field lymphadenectomy by two experienced surgeons. Distal 
tumors and those around the gastro-esophageal junction were approached through a left 









































cranial located esophageal tumors were approached through a right thoraco-laparotomy 
with cervical anastomoses.
tee prevention
Patients using preoperative anticoagulation and those diagnosed with a TEE during neoad-
juvant CRT, were instructed to use a therapeutic dosage (11400 units a day) of low molecu-
lar weight heparin (LMWH), which was adjusted to a prophylactic dose (2850 units a day) 5 
days before surgery. This was administered by specialized home care nurses. In all patients, 
LMWH was started perioperatively and continued until discharge. Dosage was dependent 
on patient’s weight and risk-factors and varied between 2850 and 11400 units a day. In 
addition, all patients received compression stockings for the first 24 hours after surgery.
Definition of outcome
The primary outcome was based on the occurrence of TEE’s pre- and/or postoperative. Venous, 
arterial, symptomatic, and idiopathic TEE’s were included. In patients treated with neoadjuvant 
CRT, a staging multidetector CT (MDCT) with intravenous and oral contrast was performed < 4 
weeks before CRT. In all patients, regardless of treatment, a MDCT with intravenous and oral 
contrast was performed < 4-8 weeks before surgery. If pulmonary embolism was diagnosed, an 
upper and lower ultrasonography was performed. Patients presented with clinical symptoms 
of TEE underwent an additional triphasic CT-angiography to confirm the diagnosis. Clinical 
suspected TEE’s of the extremities were confirmed by duplex ultrasonography. A preopera-
tive TEE took place between diagnosis of esophageal cancer and surgery. Postoperative TEE’s 
occurred during hospital admission and examination consisted of CT-angiography if central 
embolisms were suspected and duplex untrasonography to confirm TEE’s of the extremities. 
Thromboembolic events were scored according to the National Cancer Institute common 
toxicity criteria for adverse events (CTCAE version 4.03.13) (Table 1). Short-term mortality 
included in hospital mortality and/or mortality within the first 90 days after surgery.
table 1. Grading of thromboembolic events according to the Common Terminology Criteria for Adverse 
Events (CTCAE) definition:
Grade Definition
1 Venous thrombosis (e.g. superficial thrombosis)
2 Venous thrombosis (e.g. uncomplicated deep vein thrombosis), medical intervention indicated
3 Thrombosis (e.g. uncomplicated pulmonary embolism, non-embolic cardiac mural thrombus), 
medical intervention indicated
4 Life-threatening (e.g. pulmonary embolism, cerebrovascular event, arterial insufficiency) 












































Data is reflected as frequencies, means and/or median with percentages. Categorical 
variables were analyzed with the χ2 test, and continuous variables were analyzed with a 
Student t test (normal distribution) or Mann Whitney U-test (skewed distribution). Univari-
ate regression analysis was used to determine risk factors for the development of TEE’s. 
Multivariate logistic regression was applied to correct for cofounders. A p-value < 0.05 
was considered to be significant. Statistical analyses were conducted by the statistical 
software from SPSS 20.0 (SPSS Inc., Chicago IL, USA).
reSultS
Median age in this cohort was 65.8 years and the majority was diagnosed with adeno-
carcinoma 83.3% (N = 280). Hypertension (30.4%) and diabetes mellitus (12.8%) were 
the most frequently reported comorbidities. A considerable number of patients had a 
thromboembolic event in medical history, including pulmonary embolism in 2.4% (N = 8) 
and myocardial infarction in 12.2% (N = 41) (Table 2).
The majority (80.1%) of the patients underwent the full neoadjuvant treatment regimen. 
For various reasons and complications during neoadjuvant CRT, 20 patients (18.2%) re-
ceived four out of five cycles of chemotherapy and three patients (2.7%) received three 
cycles or less. Most frequently reported complications during neoadjuvant CRT consisted 
of hematological toxicity (N = 11; 10.0%) (Table 3).
matching
No differences were observed in comorbidity, histology, localization, and side of thoracotomy 
between patients with surgery alone and patients treated with neoadjuvant CRT followed 
by surgery (Table 2). However, patients treated with neoadjuvant CRT had comprehensible a 
lower ASA classification (p = 0.003). Besides, a significant difference in preoperative T stage 
(p = 0.032) was observed. These variables might influence the development of TEE’s. After 
matching, statistically comparable groups were created, with 95 patients in the surgery 
alone group and 110 patients in the neoadjuvant CRT followed by surgery group (Table 2).
thromboembolic events
In the whole cohort (N = 336), 24 patients (7.1%) were diagnosed with a TEE at some stage 
during treatment, 10 (3.0%) events developed in the preoperative phase and 14 (4.2%) 
arose postoperatively. Patients who were treated with neoadjuvant CRT were diagnosed 










































In the matched cohort (N = 205), 16 patients (7.8%) were diagnosed with a TEE of which 9 
(4.4%) occurred preoperatively and 7 (3.4%) postoperatively (Table 3). In this cohort, the 
relative risk to develop a TEE for patients treated with neoadjuvant CRT was 3.755 (95% 
CI: 1.027-13.734 p = 0.046).
table 2. Patients and tumor characteristics; surgery alone vs. neoadjuvant CRT followed by surgery.
Characteristic Surgery alone (%) neoadjuvant Crt 









Gender (M/F) 180/45 71/24 83/27 0.331 0.906
Age (years) 65.5 64.2 63.0 0.228 0.557 
Smoking 70 (31.0) 34 (35,8) 48 (43.6) 0.258 0.375 
Comorbidity
Angina pectoris 20 (8.8) 5 (5.3) 10 (9.1) 0.942 0.294
Myocardial infarction 30 (13.3) 10 (10.5) 11 (10.0) 0.390 0.901 
Heart failure 6 (2.7) 1 (1.1) 2 (1.8) 0.637 0.649 
Hypertension 64 (28.3) 25 (26.3) 38 (34.5) 0.244 0.203 
Diabetes mellitus 27 (11.9) 9 (9.5) 16 (14.5) 0.503 0.268 
TIA/CVA 21 (9.3) 4 (4.2) 7 (6.4) 0.362 0.495 
Pulmonary embolism 7 (3.1) 0 (0.0) 1 (0.9) 0.217 0.352 
DVT 7 (3.1) 0 (0.0) 2 (1.8) 0.496 0.187 
aSa classification
ASA I 11 (4.9) 10 (10.5) 13 (11.8)
ASA II 130 (57.5) 71 (74.7) 66 (60.0)   
ASA III 67 (29.6) 14 (14.7) 16 (14.5)   
ASA IV 5 (2.2) 0 (0.0) 0 (0.0)   
Missing 13 (5.8) 0 (0.0) 15 (13.6) 0.003 0.702 
histology
Adenocarcinoma 190 (84.1) 75 (78.9) 90 (81.8)
SCC 36 (15.9) 20 (21.1) 20 (18.2) 0.728 0.512 
Clinical t stage
T1 29 (12.8) 3 (3.2) 0 (0.0)
T2 32 (14.2) 12 (12.6) 19 (17.3)   
T3 158 (69.9) 75 (78.9) 86 (78.2)   
T4 7 (3.1) 5 (5.3) 5 (4.5) 0.032 0.235 
localization
Mid esophagus 25 (11.2) 14 (14.7) 14 (12.7)
Distal esophagus 160 (71.4) 62 (65.3) 85 (77.3)   
GEJ 39 (17.4) 19 (20.0) 11 (10.0) 0.201 0.097 
thoracotomy
Left sided 100 (44.2) 33 (34.7) 41 (37.3)
Right sided 126 (55.8) 62 (65.3) 69 (62.7) 0.224 0.706 
TIA/CVA: transient ischemic attack/ cerebrovascular accident, DVT: deep venous thrombosis, ASA: American 











































During the preoperative period in the unmatched cohort, 10 patients were diagnosed with 
a TEE of which 9 patients were treated with neoadjuvant CRT (p = 0.000). In the matched 
cohort all preoperative TEE’s (N = 9, 8.2%) were exclusively observed in the group treated 
with neoadjuvant CRT (p = 0.004). Thromboembolic events consisted of DVT (N = 2), pul-
monary embolism (N = 7) and portal vein thrombosis (PVT; N = 1) (Table 4). One patient 
was diagnosed with a DVT and pulmonary embolism at the same time.
The majority of the preoperative TEE’s were asymptomatic (pulmonary embolism: N = 6 
and PVT: N = 1, CTCAE 3; definition Table 1). None of these TEE’s were diagnosed on the 
first staging CT-scan, but were diagnosed on the second i.e restaging CT-scan after neoad-
juvant CRT. One patient experienced acute symptoms of a pulmonary embolism (CTCAE 
4).
Patients who were diagnosed with a preoperative TEE had a median of 60 days between 
end of neoadjuvant CRT and surgical resection compared to 48 days for patients without 
the presence of a TEE (minimum 41 days, maximum 236 days) (p = 0.021). This delay had 
no influence on the surgical decision to perform a radical resection. None of these pa-
tients were excluded from surgery. Patients who were using anti-coagulation (i.a. heparin, 
acenocoumarol or thrombocyte aggregation inhibitors) did not have a reduced risk on the 
formation of TEE’s (p = 0.758). Besides, the presence of TEE treated preoperatively had no 
influence on postoperative complications, hospital stay or short-term mortality.
A multivariate analysis was performed to correct for cofounding factors for developing pre-
operative TEE’s. History of DVT (p = 0.005; odds ratio (OR): 37.429; 95% CI: 3.025-463.117) 
table 3. Complications during neoadjuvant CRT.
Complications neoadjuvant Crt followed by 
surgery (n = 110) (%)
Grade *
1 2 3 4
Thrombocytopenia 5 (4.5) - 4 1 -
Leukopenia 7 (6.4) 1 3 3 - 
Thromboembolic event 9 (8.2) - 1 7 1 
Fever 4 (3.6) 2 2 - - 
Fatigue 2 (1.8) - 2 - - 
Dyspnea 1 (0.9) - 1 - - 
Neurotoxic effects 3 (2.7) 2 1 - - 
Nausea 2 (1.8) - 1 1 - 
Anorexia 4 (3.6) - 3 1 - 
Aspiration pneumonia 1 (0.9) - 1 - - 
Angina pectoris 2 (1.8) - 2 - - 
None 80 (72.7) - - - - 









































and treatment with neoadjuvant CRT (p = 0.004; OR: 34.519; 95% CI: 3.086-386.101) were 
identified as possible risk factors (matched cohort).
Postoperative tee
A thromboembolic complication in the postoperative course was a relatively rare event 
(N = 14; 4.2%). In the unmatched cohort 11 patients (4.8%) with surgery alone developed 
a TEE compared to 3 patients (2.7%) treated with neoadjuvant CRT (p = 0.357). These 
events varied between DVT (surgery alone: N = 1 and neoadjuvant CRT followed by 
surgery: N = 1), CVA (surgery alone: N = 2), myocardial infarction (surgery alone: N = 1) 
and pulmonary embolism (surgery alone: N = 7 and neoadjuvant CRT followed by surgery: 
N = 2) without significant differences between groups. The occurrence of a TEE in the 
matched cohort was not significantly different between both groups (N = 4 vs. N = 3; 
p = 0.560) (Table 4).
Two patients deceased within 90 days and/or in-hospital due to the consequences of a 
TEE (myocardial infarction and pulmonary embolism, CTCAE 5). These events were exclu-
sively observed in patients who underwent surgery alone. Hospital- (p = 0.936) and ICU 
stay (p = 0.375) did not differ between patients with and without TEE’s (matched cohort).
Compared to preoperative risk factors, postoperative risk factors analyses for the develop-
ment of TEE’s were extended with ICU/hospital stay and side of thoracotomy. However, 
the only possible risk factor that exceeded the threshold in univariate analysis was a his-
tory of pulmonary embolism (p = 0.012; OR: 8.778; CI 95%: 1.602-48.095).
table 4. Thromboembolic events during EC treatment.
thromboembolic
events
Surgery alone neoadjuvant Crt 










DVT 1 0 2 0.208 0.187
Pulmonary embolism 0 0 7 0.000 0.012 
PVT 0 0 1 0.487 0.708 
Patients with a TEE 1 0 9 0.000 0.004 
Postoperative
DVT 1 0 1 0.602 0.352
CVA 2 1 0 0.322 0.281 
Myocardial infarction 1 0 0 0.845 - 
Pulmonary embolism 7 3 2 0.496 0.535 
Patients with a TEE 11 4 3 0.357 0.560 











































Cancer patients generally present with a higher risk of thromboembolic events (TEE’s) and 
with the introduction of neoadjuvant chemoradiotherapy the incidence of TEE’s seems to 
increase further (6, 9, 11). In this study, we observed a higher risk of preoperative throm-
boembolic events in EC patients treated with platinum-based neoadjuvant CRT. Despite a 
possible long-lasting effect of chemoradiotherapy, we could not demonstrate a different 
postoperative incidence. Although the majority of the preoperative diagnosed TEE’s were 
idiopathic, one patient experienced acute and life-threatening symptoms of a pulmonary 
embolism during neoadjuvant CRT (CTCAE 4).
The pathophysiological mechanism is not fully understood, but chemotherapy appears 
to play a major role in pro-inflammatory and pro-coagulant response due to endothelial 
disruption. Inflammatory response is initiated by cytokines, in particular TNF-a and IL-1, 
which decrease the concentration of important anti-coagulant proteins, including anti-
thrombin and protein C. Pro-coagulant response is initiated by an increased tissue factor 
expression(6, 12). Moreover, the activated pro-coagulant response is sustained for up to 6 
months after induction of chemoradiotherapy, which implies an increased postoperative 
risk for TEE’s over a longer period of time(7).
Most scientific research concerning TEE’s in cancer patients is related on patients with 
advanced malignancies undergoing palliative treatment. Only a few studies focused on 
the incidence of TEE’s in patients who were treated with curative intent in a multimodality 
approach(5, 7, 8). In a study of Verhage et al. patients with pre- and postoperative che-
motherapy showed a significant increased incidence of preoperative TEE’s(5). In addition, 
Byrne et al. gave the pathophysiological explanation for an increased risk of TEE’s in a 
multimodal treatment(7). In gastro-esophageal cancer patients treated according to the 
CROSS regimen, the risk for TEE’s is not previously described(1). Additional risk factors 
for cancer-associated TEE’s are well documented in the literature and are generally based 
on cancer treatment –and patient related factors(4). In accordance to our results, a past 
history of thrombotic events is a risk factor for developing TEE’s.
In the current study, we applied perioperatively thromboprophylaxis with compression 
stockings and low molecular weight heparin (LMWH), which was continued until dis-
charge. Nevertheless, 14 patients were diagnosed with postoperative TEE’s of whom two 
were fatal (surgery alone group). Generally, patients did not receive primary or secondary 
thromboprophylaxis in the preoperative period. The value and safety of prophylaxis during 
chemoradiotherapy is questionable, as it may contribute to an increased risk of bleeding 
in combination with chemotherapeutic induced thrombocytopenia (13). The incidence 
of thrombocytopenia in this study is probably underestimated due to the retrospective 









































to-treat to prevent a symptomatic TEE was 60 without any clear benefit in survival, but 
with an increased risk of complications(13). Preoperative TEE’s in the present study were 
not only associated with chemoradiation, but also with a history of DVT. Hence, current 
guidelines recommend secondary thromboprophylaxis in cancer patients with a history 
of TEE’s(14). Notwithstanding the lack of an appropriate study design, but based on the 
results of present study and previous published guidelines, we recommend the use of sec-
ondary thromboprophylaxis during neoadjuvant CRT in EC patients with a history of TEE’s. 
In our opinion, it is preferable to start thromboprophylaxis with LMWH under adequate 
hematological control(15).
The majority of preoperatively diagnosed TEE’s in the present study were asymptomatic. 
None of these TEE’s in patients treated with neoadjuvant CRT were diagnosed at the first 
staging CT-scan, but during the second i.e restaging CT-scan 4-8 weeks prior to surgery. 
The staging CT-scan in patients within the surgery alone group also was performed < 4-8 
weeks before surgery. We therefore do not expect an underestimated incidence of preop-
eratively diagnosed TEE’s in patients without neoadjuvant CRT. In current study, patients 
without clinical suspicion of TEE did not undergo a triphasic CT-angiography. However, the 
diagnostic accuracy of currently used multislice MDCT with intravenous contrast seems 
to be of sufficient quality in diagnosing pulmonary embolism, especially when combined 
with an upper and lower ultrasonography(16-18). Therefore, we consider the impact of 
neoadjuvant CRT on the development of TEE’s plausible by this study and available litera-
ture(5, 7-9, 13). Nevertheless, with one symptomatic pulmonary embolism, the impact 
of TEE’s seems relatively moderate. And in spite of a significant delay until surgery, there 
seemed to be no influence on surgical resection and postoperative course(8).
In conclusion, patients treated with neoadjuvant CRT for esophageal cancer have an 
increased risk to develop TEE’s for surgical resection, especially with TEE’s in medical his-
tory. Postoperatively we observed no difference in incidence. We therefore, make a plea 
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Background: Neoadjuvant chemoradiotherapy (CRT) improves loco-regional control and 
overall survival in esophageal cancer patients. Although adverse events are relatively low 
during neoadjuvant CRT, severe postoperative side-effects may occur leading to morbidity 
and even mortality. We investigated the impact of a more frequently used neoadjuvant 
CRT regimen of 41.4Gy/5wks radiotherapy with concurrent Carboplatin and Paclitaxel 
(CROSS schedule) on the postoperative course.
methods: Between 2006 and 2012, a total of 96 esophageal cancer patients (staged 
cT1N+/T2-4a/N0-3 and M0) were treated according to the above neoadjuvant scheme. To 
reduce bias in this single center study, we performed a propensity score matched analysis 
with patients who underwent surgery alone (n = 230), from a prospectively maintained 
database (n = 326).
results: Baseline characteristics between both groups were equally distributed in the 
matched cohort. In the neoadjuvant treated group significantly more patients were di-
agnosed with pneumonia (27.1% vs. 51.0%; p = 0.001), pleural effusion (12.5% vs. 24.0%; 
p = 0.040), and arrhythmias (20.4% vs. 34.4%; p = 0.008). Besides, in the multivariate 
analysis neoadjuvant CRT was significantly associated with an increased risk of pneumonia 
(p = 0.001, odds ratio (OR) 2.896), pleural effusion (p = 0.041, OR 2.268), and arrhythmia 
(p = 0.023, OR 2.215). Despite these outcomes, no differences were detected in ICU - or 
hospital stay. Short-term mortality did not differ between both groups.
Conclusions: In this study, we observed an increase of cardiopulmonary complications 
in the neoadjuvant CRT group, which has no effect on hospital or ICU stay and mortality. 











































Survival in esophageal cancer patients after curative intended surgery alone remains 
poor with an average 5-year disease free survival between 15–25% [1]. To improve loco-
regional control and overall survival, a multimodality approach with neoadjuvant chemo-
radiotherapy (CRT) has become standard of care in most centers. Significant survival 
benefit of 13% at 5 years after neoadjuvant CRT has been demonstrated in a multicenter 
randomized clinical trial, the CROSS study [2]. Based on their results and the outcome 
in the literature over the last decades, the authors make a plea for standardization of 
preoperative CRT[2-15].
Transthoracic esophagectomy is generally considered to be a high-risk surgical procedure 
with complication rates ranging between 40-60% [16]. With an even more onerous treat-
ment policy, concerns have been raised about the impact of neoadjuvant CRT on the 
postoperative course. Chemotherapy prior to a radical esophagectomy may subsequently 
be accompanied by the risk of acute and late toxicity. Adding thoracic radiotherapy to a 
combined chemotherapy regimen will further increase cardiopulmonary toxicity [17, 18]. 
It might induce acute inflammation resulting in pneumonia, pleural effusion and finally 
lung fibrosis and is associated with a significant cardiac toxicity [19].
Nevertheless, promising results for long term survival have led to several randomized 
controlled trials (RCT’s) and subsequent meta-analyses [2, 9-15, 20]. Some studies de-
scribed an increased postoperative morbidity and even mortality, which was not the case 
in the CROSS trial. However, postoperative morbidity in that study was described without 
further specification in postoperative complications.
With aging of the population and increased incidence of esophageal cancer in western 
countries the use of neoadjuvant CRT will further increase. Especially in elderly patients 
the prevalence of comorbidity is relatively high and we should consider whether long-
term survival benefits outweigh the potential disadvantages of higher complication rates 
[4]. In addition, comorbidities contribute to complexity and restricting patients from CRT 
in the pretreatment assessment remains difficult. In this study we aimed to investigate 




From a prospectively maintained database we included all 326 esophageal cancer pa-










































between January 2000 and June 2012. From this group we collected the following data: 
demographic characteristics, comorbidity, neoadjuvant treatment, tumor characteristics, 
therapeutic information, complications, and survival data. Of these 326 patient, 96 pa-
tients were treated with the CROSS regimen. To reduce bias in selection criteria and inter-
fering factors in postoperative complications, we created statistically comparable groups 
by propensity matching. The propensity score is used to balance covariates allowing two 
study subjects with the same propensity score to be appreciably similar in observed 
table 1. Patient characteristics
variable Surgery alone (%) neoadjuvant 









Median age (yrs) 65.0 63.1 62.7 0.427 0.432
Sex (M/F) 180/50 72/24 71/25 0.400 0.869 
Smoker 30.6 34.7 42.7 0.205 0.258 
histology
Adenocarcinoma 191 (83.0) 79 (82.3) 77 (80.2) 0.608 0.527
Squamous CC 37 (16.1) 16 (16.7) 19 (19.8) 
Other 2 (0.8) 1 (1.0) 0 (0.0) 
localization
Mid 25 (10.9) 10 (10.4) 13 (13.5)
Distal 162 (70.4) 66 (68.8) 73 (76.0)   
GEJ 43 (18.7) 20 (20.8) 10 (10.4) 0.140 0.123 
ct stage
T1/T2 61 (26.5) 27 (28.1) 23 (24.0)
T3/T4 169 (73.5) 69 (71.9) 73 (76.0) 0.844 0.492 
Comorbidity
Angina pectoris 18 (7.8) 10 (10.4) 6 (6.3) 0.619 0.296
Myocardial infarct 29 (12.6) 11 (11.5) 8 (8.3) 0.267 0.468 
Heart failure 5 (2.2) 2 (2.1) 2 (2.1) 0.959 1.000 
Hypertension 66 (28.7) 32 (33.3) 31 (32.3) 0.517 0.878 
COPD 33 (14.3) 6 (6.3) 7 (7.3) 0.077 0.774 
Diabetes mellitus 27 (11.7) 9 (9.4) 13 (13.5) 0.651 0.365 
TIA/CVA 20 (8.7) 3 (3.1) 7 (7.3) 0.675 0.194 
aSa classification
ASA I 11 (5.1) 10 (11.2) 11 (13.6)
ASA II 136 (62.7) 67 (75.3) 57 (70.4)   
ASA III 65 (30.0) 11 (12.4) 13 (16.0)   
ASA IV 5 (2.3) 1 (1.1) 0 (0.0) 0.006 0.649 
thoracotomy
Right sided 129 (56.1) 56 (58.9) 59 (61.5)









































dimensions (implemented in our SPSS package [21]). The 96 patients in the neoadjuvant 
CRT group were matched with 96 patients from the total 230 patients treated with surgery 
alone. Patients were matched for: age, sex, tumor characteristics, comorbidity (individu-
ally scored: diabetes mellitus, hypertension, angina pectoris, heart failure, myocardial 
infarction, COPD, TIA/CVA), ASA score and side of thoracotomy (Table 1).
neoadjuvant chemoradiotherapy
Both squamous cell carcinoma and adenocarcinoma of the esophagus were considered 
suitable for neoadjuvant CRT. Oncologic criteria consisted of a clinical tumor stage of 
T1N1-3 or T2-T4aN0-3 without distant metastases (M0). During 2006-2008, a part of our 
cohort participated in the national CROSS study [2]. After 2008 neoadjuvant CRT was 
administered based on the judgment of the oncologist, on inclusion criteria similar to that 
used in the CROSS study. Carboplatin was administered weekly to achieve an area under 
the curve (AUC) of 2 mg per milliliter per minute and paclitaxel of 50 mg/m2 for 5 weeks, 
with concurrent radiotherapy, which consisted of 41·4 Gy in daily fractions of 1·8 Gy (in 
3 patients 45·0 Gy in 25 fractions), five times per week. Radiotherapy target volumes 
were delineated on a planning CT-scan by an experienced radiation oncologist using all 
diagnostic information.
Surgery
All patients with cardiopulmonary history were seen by the cardio/pulmonologist for 
perioperative recommendations. After a restaging CT, 4 weeks after the end of CRT, 
patients were planned for a surgical resection, usually within 4-8 weeks after neoadju-
vant treatment. All patients underwent a transthoracic esophagectomy with two-field 
lymphadenectomy by two experienced surgeons. Tumors around the gastroesophageal 
junction were approached through a left thoraco-laparotomy while more cranial located 
esophageal tumors were approached through a right-sided procedure.
Definitions of outcome
Short-term mortality was defined as “surgical mortality” which included in hospital mor-
tality and/or mortality within the first 90 days after operation. To simplify comparison 
with previous studies, 30-day mortality was also displayed. Complications during hospital 
admission were divided into pulmonary, cardiac, and other complications as can be seen 
in Table 2. Complications were scored on the same criteria as described previously [22], 
except for pneumonia, which was supplemented with the use of antibiotic treatment on 
clinical indications.
Comorbidity was classified according to the American Society of Anesthesiology (ASA) 











































Data was reflected as frequencies, means and/or medians with percentages. Categorical 
variables were analyzed with the χ2 test, and continuous variables were analyzed with 
a Student t test (normal distribution) or Mann Whitney U-test (skewed distribution). To 
determine the effect of neoadjuvant CRT on postoperative complications, we performed 
a multivariate analysis for complications with a p-value < 0.1 in the univariate analyses. A 
p-value < 0.05 was considered to be significant. All statistical analyses were conducted by 
the statistical software from SPSS 20.0 (SPSS Inc., Chicago IL, USA).
table 2. Matched data; complications and post-operative course after esophagectomy
variable Surgery alone
n = 96 (%)
neoadjuvant Crt followed by surgery 
n = 96 (%)
p-value
Surgical mortality* 7 (7.3) 7 (7.3) 1.000
30-day mortality 6 (6.3) 3 (3.1) 0.306 
Overall complications 60 (62.5) 70 (72.9) 0.123 
Pulmonary complications
Respiratory failure 26 (27.1) 22 (22.9) 0.505
Pneumonia 26 (27.1) 49 (51.0) 0.001 
ARDS 5 (5.2) 2 (2.1) 0.248 
Atelectasis 10 (10.4) 9 (9.4) 0.809 
Pleural effusion 12 (12.5) 23 (24.0) 0.040 
Pulmonary embolism 3 (3.1) 2 (2.1) 0.650 
Re-intubation 25 (26.0) 18 (18.8) 0.226 
Cardiac complication
Arrhythmias 20 (20.8) 33 (34.4) 0.036
Myocardial infarct 2 (2.1) 0 (0.0) 0.155 
other complications
SIRS 5 (5.2) 4 (4.2) 0.733
Sepsis 9 (9.4) 7 (7.3) 0.602 
Anastomotic leakage 13 (13.5) 11 (11.5) 0.663 
Chylothorax 3 (3.1) 7 (7.3) 0.194 
Wound infections 9 (9.4) 8 (8.3) 0.799 
Wound dehiscence 4 (4.2) 2 (2.1) 0.407 
Renal failure 4 (4.2) 4 (4.2) 1.000 
Liver failure 0 (0.0) 1 (1.0) 0.316 
Ileus 2 (2.1) 4 (4.2) 0.407 
Postoperative course
Reoperation 6 (6.3) 8 (8.3) 0.579
OR-time 7.8 hours 9.0 hours 0.158 
ICU-stay 3.5 days 3.0 days 0.954 
Hospital stay 16.0 days 16.0 days 0.986 










































Differences in demographic characteristics between patients who were treated with 
surgery alone (group 1, N = 230) and those treated with neoadjuvant CRT combined with 
surgery (group 2, N = 96), were only observed in ASA classification (p = 0.006) (Table 1). 
After matching, 96 patients were included in group 1 and 96 in group 2 with an equal 
distribution of demographic characteristics (Table 1). The majority (95.8%) of this cohort 
received at least 4 out of 5 cycles of the neoadjuvant CRT scheme.
mortality and morbidity
Short-term mortality was not significantly different between both groups. In the un-
matched cohort we observed a 30-day mortality of 4.3% (n = 14), which was equally 
distributed between both groups. Surgical mortality in the unmatched cohort, including 
in-hospital and 90-day mortality, was 7.4% (N = 17) for group 1 and 7.3% (N = 7) for group 
2 (p = 0.975). In the matched cohort, surgical mortality was 7.3% (N = 7) for both groups 
(p = 1.000). Overall morbidity rates in the matched cohort between group 1 (62.5%) and 2 
(72.9%) were not significantly different (p = 0.123) (Table 2).
Pulmonary complications in the matched cohort
Overall pulmonary complications were observed more frequently, but not significantly 
different in patients treated with neoadjuvant CRT (46.9% vs. 59.4%; p = 0.083). Pneumo-
nia was the most commonly reported complication, and occurred significantly more in 
patients treated with neoadjuvant CRT (27.1% vs. 51.0%; p = 0.001). The number of days 
between the end of neoadjuvant CRT and surgery had no influence on the occurrence of 
pneumonia (52 days vs. 53 days; p = 0.137). In addition to pneumonia, also pleural effu-
sion was more frequently observed in patients treated with neoadjuvant CRT (12.5% vs. 
24.0%; p = 0.040). The number of days between the end of neoadjuvant CRT and surgery 
was not significantly different (56 days vs. 52 days; p = 0.958). In contrast to pneumonia, 
pleural effusion was not significantly different (p = 0.075) in the unmatched cohort. Other 
pulmonary complications were not significantly different (Table 2).
Cardiac complications in the matched groups
Cardiac complications consisted almost exclusively of arrhythmias and occurred in 20 
(20.8%) patients in group 1 versus 33 (34.4%) in group 2, which was significantly different 
(p = 0.036). Time between the end of neoadjuvant CRT and surgery seemed to have no in-
fluence on the development of postoperative arrhythmias (52 days vs. 54 days; p = 0.676). 
Also in the unmatched cohort, arrhythmias were significantly more observed in the group 










































other complications in the matched groups
None of the other complications turned out to be significantly different between patients 
treated with surgery alone compared to patients treated with neoadjuvant CRT followed 
by surgery (Table 2).
Postoperative course
Despite a higher incidence of pneumonia, patients treated with neoadjuvant CRT had a 
slightly shorter median ICU stay (3.5 vs. 3.0 days; p = 0.954) and an identical in hospi-
tal stay (16.0 vs. 16.0 days; p = 0.986). The number of reoperations (6.3% versus 8.3%; 
p = 0.579) appeared to be similar as well.
multivariate analysis
To determine the influence of neoadjuvant CRT on the development of postoperative 
complications, we performed a multivariate analysis for complications with a p-value < 0.1 
in univariate analyses. Neoadjuvant CRT (p = 0.001, odds ratio (OR): 2.896) and side of 
thoracotomy, at the prejudice of a right-sided approach (p = 0.020, OR: 2.134) were 
significantly associated with the development of pneumonia. Pleural effusion was associ-
ated with neoadjuvant CRT (p = 0.041, OR: 2.268) and side of thoracotomy (p = 0.004, OR: 
3.951). Risk factors for arrhythmias were neoadjuvant CRT (p = 0.023, OR: 2.215) and age 
(p = 0.000, OR: 1.084) (Table 3).
Multivariate analysis in the unmatched data revealed similar results. In comparison to 
the matched data, neoadjuvant CRT (p = 0.001, OR: 2.333) and side of thoracotomy at 
the prejudice of a right-sided approach (p = 0.009, OR: 1.906) were associated with the 
development of pneumonia. Pleural effusion was not significantly associated with neoad-
juvant CRT in the unmatched data, but with heart failure (p = 0.010, OR: 8.414), history of 
table 3. Significant outcomes in multivariate analyses
matched data Pneumonia Pleural effusion arrhythmias
OR 95% CI OR 95% CI OR 95% CI
Neoadjuvant CRT 2.896 1.566-5.357 2.268 1.035-4.969 2.215 1.114-4.403
Side of thoracotomy 2.134 1.127-4.042 3.951 1.540-10.141 - - 
Age - - - - 1.084 1.037-1.133 
unmatched data
Neoadjuvant CRT 2.333 1.423-3.826 - - 2.503 1.426-4.395
Side of thoracotomy 1.906 1.179-3.081 2.433 1.221-4.848 - - 
Heart failure - - 8.414 1.670-42.391 6.690 1.197-37.389 
History of smoking - - 1.890 1.008-3.544 - - 









































smoking (p = 0.047, OR: 1.890), and side of thoracotomy at the prejudice of a right-sided 
approach (p = 0.011, OR: 2.433). Finally, arrhythmias were associated with neoadjuvant 
CRT (p = 0.001, OR: 2.503), age (p = 0.000, OR: 1.066), and in contrast to the matched 
data, also with heart failure (p = 0.030, OR: 6.690).
DISCuSSIon
Current study demonstrates an increased incidence of postoperative pneumonia, pleural 
effusion, and arrhythmias by approximately twofold after the introduction of neoadjuvant 
chemoradiotherapy. Although these outcomes suggest an increased risk for prolonged 
ICU and/or hospital stay or even mortality risk, this was not confirmed by present data.
After the positive impact of neoadjuvant CRT in the multicenter randomized CROSS 
trial, the acceptance in daily management has increased for the current used regimen 
of radiotherapy with concurrent carboplatin and paclitaxel to improve overall survival 
[2]. However, the role of CRT prior to the esophagectomy has been debated for several 
decades. Part of this prolonged discussion was the occurrence of toxic cardiopulmonary 
adverse events and consequently a raised postoperative risk for morbidity and mortality 
[6]. Besides cardiopulmonary complications, inflammation and anastomotic leakage were 
also feared [8].
The pathophysiological correlation between radiation dose to the lungs and the risk of 
pulmonary complications has been demonstrated by several studies [17, 18]. Wang et al. 
found that the volume of the lung spared from doses of ≥ 5 Gy was the only independent 
dosimetric factor for the risk of postoperative pulmonary complications (defined as pneu-
monia or ARDS). This suggests that a lower dose of radiotherapy in a multimodality treat-
ment leads to a minimization of irradiated lung volume and might reduce the incidence 
of pulmonary complications. The radiation dose to the heart in the neoadjuvant setting 
of distal esophageal cancer is quite substantial, despite the relatively low total radiation 
dose. Radiation to the pericardium increases the risk of pericardial effusion, which seems 
to be dose-dependent [24]. Arrhythmia might display radiation-induced cardiac toxicity. 
However, little is known about the correlation between arrhythmia and radiotherapy in 
esophageal cancer patients. Moreover, paclitaxel may induce ventricular arrhythmias, 
bradycardia and several degrees of atrioventricular conduction blocks [25]. It is essential 
to reduce the amount of radiation on cardiopulmonary organs without compromising the 
beneficial effect of radiotherapy. Improvements of advanced radiation technologies using 











































Conflicting data have been reported over the past years about the influence of neoad-
juvant CRT on the postoperative course [2-8]. Merritt R.E. et al. concluded that major 
complications would not appear to increase due to neoadjuvant CRT, but were associated 
with the transthoracic approach and preoperative coronary artery disease [7]. Similar 
results were reported whereby neoadjuvant CRT did not appear to be an important pre-
dictor of major morbidity and mortality after esophagectomy, not even in elderly patients 
[4]. However, other reports did identify an increased incidence of pulmonary and septic 
complications after neoadjuvant CRT [6]. These different outcomes may be explained by 
considerable bias due to different neoadjuvant regimens in terms of dose or schedule for 
both chemotherapy and radiation. Chemotherapy based on cisplatin and/or 5-fluorouracil 
(5-FU) generally has more intense adverse side effects compared to the combination of 
carboplatin/paclitaxel [25, 27]. Additionally, there is a lack of uniformity in postoperative 
definitions and comparison of non-homogeneous groups without any correction for dif-
ferences in surgical approach [28].
Besides uncertain effects of neoadjuvant CRT in developing postoperative complications, 
there is still doubt about the “ideal time period” after preoperative CRT and surgical 
resection. In this study, although it was not our main purpose, we could not demonstrate 
any correlation between these variable and postoperative complications. In rectal cancer, 
delayed surgery beyond 8 weeks after neoadjuvant CRT seemed to reduce postoperative 
morbidity without compromising prognosis [29].
Although significantly different between both groups, the cardiopulmonary complications 
in this study seemed to be relatively high. This might be explained by the fact that all pa-
tients underwent a transthoracic esophagectomy, which has a relatively higher morbidity 
and/or mortality rate [7]. Moreover, we used comprehensive definitions for postoperative 
complications, but the incidence of postoperative morbidity did not result in an increased 
mortality.
Awareness of clinicians could reduce postoperative complications when treatment is 
started earlier or even immediate postoperative as a preventive strategy [30, 31]. Cur-
rently, neoadjuvant CRT is given in our institution to patients with a comparable condi-
tional status as was based on the inclusion criteria of the CROSS trial. Patients with a 
considerable frailty during pre-treatment assessment are excluded for neoadjuvant CRT. 
Indeed, our results underline a cautious use of neoadjuvant CRT in this group of patients, 
given the increased risk of cardiopulmonary complications. Therefore, we make a plea for 
an individualized treatment strategy in which neoadjuvant CRT plays an important role. 
Unfortunately, an objective measurement to properly assess the condition of the patient 










































This study shows an increased incidence of pneumonia, pleural effusion and arrhythmia 
after neoadjuvant chemoradiotherapy, without increasing the mortality risk in the treat-
ment of esophageal cancer patients. In multivariate analysis neoadjuvant chemoradio-
therapy was significantly associated with the risk of pneumonia and arrhythmia. Further 
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Introduction: To reduce the severity of postoperative (p.o) complications after esophagec-
tomy in esophageal cancer (EC) patients, early identification is of great importance. We 
evaluated the prognostic value of early (< 48 hrs) p.o routine peripheral blood measure-
ments for complications during hospital stay and short-term mortality (< 90 days) after 
transthoracic esophagectomy (TTE).
methods: Between 2006 and 2012, blood samples of 210 EC patients were analyzed on 
three consecutive time points: 0 (T1), 24 (T2) and 48 (T3) hours after resection for albumin 
(Alb), creatinine, C-reactive protein (CRP), lactate dehydrogenase (LDH), white blood cell 
count (WBC), platelet count and hemoglobin (Hb). Multivariate analysis was performed on 
factors with p-values ≤ 0.1 at univariate analysis. Significant results were further analyzed 
by applying an area under the Receiver Operator Curve (AUC) to determine discriminatory 
power.
results: Sepsis and anastomotic leakage were moderately predicted by LDH at T2 (OR: 
1.012; AUC: 0.71 and OR: 1.008; AUC: 0.71 respectively), whereas CRP at T3 was associated 
with sepsis (OR: 1.008; ROC: 0.72). Renal failure was strongly associated with creatinine at 
T2 (OR: 1.039; ROC: 0.74). Short-term mortality (N = 12) was assessed by creatinine (T2) 
(OR: 1.020), but without discriminatory power (0.52).
Conclusion: Early derangements of LDH (T2), creatinine (T2) and CRP (T3) may be helpful 










































In the last three decades and particularly in elderly patients, a rising incidence of esopha-
geal cancer (EC) has been observed, resulting in the 7th most commonly diagnosed malig-
nancy worldwide[1]. For patients presenting with localized disease, surgery, usually after 
neoadjuvant chemoradiotherapy (CRT), remains important in achieving potentially cura-
tive treatment. Even though postoperative mortality has decreased, this major surgical 
procedure is associated with substantial perioperative morbidity (40-60%) and in-hospital 
mortality (3-5%)[2, 3]. Postoperative complications are mainly pulmonary related, ranging 
from pneumonia to acute respiratory failure, or infectious from other origins[4, 5]. Neo-
adjuvant CRT seems to increase the susceptibility of both pulmonary and inflammation 
related complications[6].
It is important to identify early signs of a potentially complicated postoperative course 
after esophagectomy, which could lead to a more effective management with eventually 
lower mortality and shorter stay at the intensive care unit (ICU)[7]. Currently available 
individual risk stratifications are not reliable enough to be used in established pathways 
of care and in guiding clinical decision-making[7]. However, comprehensive clinical and 
biological parameters together may increase the awareness which could be useful in 
timely treatment decisions.
Several studies analyzed the value of routine blood examination to predict postoperative 
outcome as the result of both surgical trauma and preoperative patient-related risk fac-
tors[8-16]. Complement activation and acute phase response induced by surgery, with 
marked decrease levels of albumin and elevated levels of C-reactive protein (CRP) in 
the first postoperative days was shown to contribute to postoperative morbidity[8, 17]. 
However, data on the value and degree of deviation of postoperative routine blood tests 
and the association with other putative interfering factors in predicting postoperative 
complications and mortality are scarce or inconsistent. A correct interpretation of abnor-
mal blood tests after esophagectomy could result in a better insight of the postoperative 
course in EC patients. In this study we analyzed the correlation between early routine 




Between 2006 and 2012, 210 consecutive EC patients underwent a surgical resection with 










































demographic information, neoadjuvant treatment, tumor characteristics, therapeutic 
information, complications and survival data. For the analysis, relevant data was entered 
into a separate, anonymized database according to the rules of our Institutional Review 
Board (www.ccmo.nl)
neoadjuvant Chemoradiotherapy and surgery
Since 2006, neoadjuvant CRT consisted of carboplatin and Paclitaxel, with concurrent 
radiotherapy of 41·4 Gy in daily fractions of 1·8 Gy, five times per week was applied in 
patients with tumors staged as T1N1-3 or T2-T4aN0-3 without distant metastases (CROSS 
regimen) [18].
All patients underwent a transthoracic esophagectomy (TTE) with two-field lymphad-
enectomy by two experienced surgeons, in a tertiary referral center. Tumors around the 
gastro-esophageal junction were generally approached through a left thoraco-laparotomy 
with intrathoracic anastomosis, while more cranially located esophageal tumors were 
approached through a right sided thoracotomy with cervical anastomoses. Patients went 
postoperatively to the ICU, where they were usually extubated within 24 hours after 
surgery.
routine peripheral blood tests
After surgery, EDTA blood samples were taken on routine base. For this study we evalu-
ated seven measurements drawn in each patient up to 48 hours postoperatively at three 
different time points: immediately after surgery on arrival at the ICU (T1), ≥ 24 hours (T2) 
and ≤ 48 hours (T3) after surgery. We evaluated a total of 3850 blood values, with 560 
missing values, which were distributed randomly. The following routine serum blood mea-
surements were analyzed; hematological function tests (white blood cell count (WBC), 
platelet count (PC) and hemoglobin (Hb)); inflammatory reactions (C-reactive protein: 
CRP), albumin (Alb) and lactate dehydrogenase (LDH)); renal function test (creatinine, 
which is also a measure of muscle mass) and liver function tests (levels of LDH and Alb).
Definitions of outcome
The primary endpoints were early postoperative morbidity and short-term mortality. 
For a real estimation of postoperative mortality after esophagectomy, we defined short-
term mortality as death within the first 90 days after surgery and/or within the same 
hospital admission. Postoperative complications were identified and classified as follows: 
Pulmonary complications were defined as: pneumonia (infiltrate on X-ray with positive 
sputum culture or antimicrobial therapy on clinical indications), respiratory failure (ICU 
re-admission for respiratory support and/or re-intubation), and acute respiratory distress 









































ability, bilateral infiltrates on x-ray and severe hypoxemia requiring the need for mechani-
cal ventilation). Infectious complications were defined as: sepsis (clinical signs of SIRS, but 
with culture-proven infection or infection identified by visual inspection), anastomotic 
leakage (on oral contrast esophagography or CT and elevated amylase in drainage pleural 
fluid), renal failure (i.e. rising creatinine and oliguria requiring renal replacement therapy), 
Cardiac complications; arrhythmia (diagnosed on ECG).
Statistics
Results were presented as frequencies, means or medians with percentages and inter-
quartile range. Odds ratios (OR), confidence intervals (CI) and p-values between serum 
values and morbidity/mortality rates were determined with univariate logistic regression 
analysis. Significant outcomes with a threshold of p-value of ≤ 0.1 were further analyzed 
with multivariate analysis through a backward selection and area under the Receiver Op-
erator Curve (AUC) to determine discriminatory power. Values between 0.7-0.8 suggest 
moderate discrimination and values exceeding 0.8 suggest good discrimination. Statistical 
analyses were performed by using the statistical package of SPSS version 20.0.0 (SPSS Inc., 
Chicago, IL USA).
reSultS
Clinical characteristics, co-morbidities and complications after esophagectomy are sum-
marized in Table 1. Median age was 64.1 (range: 34.7-85.1) years. Almost half of the 
patients in this cohort received neoadjuvant CRT (96 patients; 45.7%). As depicted, many 
patients suffered from cardiovascular comorbidities. Most common postoperative compli-
cations were cardiopulmonary-related; 89 patients (42.4%) suffered from pneumonia, 45 
(21.4%) had respiratory failure and 51 (24.3%) developed arrhythmia. Short-term mortal-
ity, including in-hospital and < 90-day mortality, was 5.7% (N = 12).
routine blood values and cardio-pulmonary complications
In addition to a number of laboratory parameters, age, neoadjuvant CRT, co-morbidity, 
smoking and side of thoracotomy were associated at p-value < 0.1 in the univariate analy-
ses. After multivariate logistic regression analysis, postoperative albumin concentrations 
(T1) (OR: 0.913; 95% confidence interval (CI): 0.851-0.979) and neoadjuvant CRT (OR: 
2.127; CI: 1.157-3.909) were independent prognostic factors in developing pneumonia 
(Table 2). However, albumin at T1 had no discriminatory power in ROC analysis (0.63; 
CI: 0.55-0.71). In predicting respiratory failure, only a right sided thoracic approach was 










































table 1. Patients characteristics, preoperative co-morbidity and complication rates after esophagec-
tomy: N = 210 (%)
Characteristics (%) Comorbidity (%) Complications (%)
Mean age (yrs) 64.1 Diabetes mellitus 28 (13.3) Pneumonia 89 (42.4)
Sex (M/F) 162/48 Heart failure 4 (1.9)   
histology Myocardial infarction 25 (11.9) Respiratory failure 45 (21.4) 
Adenocarcinoma 172 (81.9) COPD 22 (10.5)   
Squamous cell ca. 37 (17.6) Smoking 85 (40.5) ARDS 5 (2.4) 
Other 1 (0.5) Pulmonary complications 101 (48.1) 
localization aSa classification Sepsis 17 (8.1) 
Mid esophagus 37 (17.6) ASA 1 13 (6.2) Leakage 21 (10.0) 
Distal esophagus 141 (67.1) ASA 2 116 (55.2) Renal failure 8 (3.8) 
GEJ 32 (15.2) ASA 3 51 (24.3) Infectious complications 40 (19.0) 
neoadjuvant Crt  ASA 4 2 (1.2) Arrhythmias 51 (24.3) 
Yes/No 96/118 Missing 28 (13.3) Re-operation 13 (6.2) 
thoracotomy    Re-admission ICU 36 (17.1) 




30-day mortality 7 (3.3) 
GEJ: Gastroesophageal Junction. COPD: Chronic Obstructive Pulmonary Disease. ARDS: acute respiratory distress 
syndrome. ASA: American Society of Anesthesiologists
table 2. Multivariate analysis of complications, only significant results in multivariate logistic regres-
sion are displayed. OR (95% CI)
Pneumonia respiratory failure arrhythmias renal failure
Albumin T1 0.913 (0.851-0.979)
Creatinine T2    1.039 (1.016-1.062) 
Age   1.094 (1.039-1.153) 
Neoadjuvant CRT 2.127 (1.157-3.909)  4.738 (1.902-11.802) 
Myocardial 
infarction 
 0.076 (0.007-0.838) 
COPD  5.312 (1.688-16.719) 
Smoking  2.790 (1.204-6.465) 
Side of thoracotomy 2.251 (1.040-4.871) 
Sepsis leakage re-admission ICu Short-term mortality
Creatinine T2 1.020 (1.001-1.039)
CRP T3 1.008 (1.001-1.016)    
LDH T2 1.012 (1.003-1.021) 1.008 (1.001-1.016) 1.006 (1.001-1.012)  
COPD 4.879 (1.089-21-869)  
Smoking 10.84 (1.97-59.50) 









































Arrhythmias were only predicted by preoperative patient and treatment-related factors 
including; age (OR: 1.094; CI: 1.039-1.153), neoadjuvant CRT (OR: 4.738; CI: 1.902-11.802), 
myocardial infarction (OR: 0.076; CI: 0.007-0.838), COPD (OR: 5.312; CI: 1.688-16.719), 
and smoking (OR: 2.790; CI: 1.204-6.465) (Table 2).
routine blood values and infectious complications
Sepsis was associated with elevated levels of CRP at T3 (OR: 1.008; CI: 1.001-1.016) with 
moderate discriminatory power (0.72; CI: 0.61-0.83) (Table 2 and Figure 1) and LDH at T2 
(OR: 1.012; CI: 1.003-1.021; AUC: 0.71; CI: 0.57-0.85) (Table 2 and Figure 2). In addition, 
 
figure 1. Postoperative sepsis and CRP (mg/l) concentrations on three time points
 










































LDH was also an independent prognostic marker in the event of anastomotic leakage (T2) 
(OR: 1.008; CI: 1.001-1.016; AUC: 0.71; CI: 0.54-0.88) (Table 2 and Figure 3). Renal failure 
was strongly associated with creatinine (T2) (OR: 1.039; CI 1.016-1.062; AUC: 0.74; CI: 
0.52-0.95) (Table 2 and Figure 4).
routine blood values and postoperative course/short-term mortality
Patients, who were re-admitted at the ICU, were predicted by elevated levels of LDH at 
T2 (OR: 1.006; CI: 1.001-1.012) (Table 2). Independent prognostic values for short-term 
 
figure 3. Postoperative anastomotic leakage and LDH (U/l) concentrations on three different time 
points
 










































mortality (in-hospital or within 90 days) were creatinine at T2 (OR: 1.020; CI: 1.001-1.039), 
side of thoracotomy to the detriment of a right-sided approach (OR: 5.49; CI: 1.00-30.07), 
and smoking (OR: 10.84; CI: 1.97-59.50) (Table 2). However, these peripheral blood mea-
surements showed to have insufficient discriminatory power in ROC analysis.
Patients with neoadjuvant CRT had significantly lower levels of creatinine (p = 0.003 mean: 
70,20 vs. 76,68), LDH (p = 0.029 mean: 218,28 vs. 238,07), WBC (p = 0.000 mean: 11,24 
vs. 14,03), and platelet counts (p = 0.000 mean: 202,89 vs. 226,48). Besides, as previ-
ously described, neoadjuvant CRT was an independent prognostic marker for developing 
postoperative pneumonia and arrhythmias.
DISCuSSIon
In improving quality of care, a better understanding in patient’s response to surgical 
trauma, which might affect survival and postoperative complications, is essential. By fo-
cusing on the first 48 hours after esophagectomy, we intended to increase the awareness 
by providing additional tools in early identification of postoperative complications, even 
before they were clinically manifest. In the present study, deranged measurements of 
LDH, creatinine and CRP showed to be of independent prognostic value and with sufficient 
discriminatory power in predicting serious postoperative complications after esophagec-
tomy.
Most centers in the Western world will determine these examined measurements daily 
in the first postoperative days. However, the interpretation of deranged values is difficult 
in clinical practice. Besides, major complications may interact with different physiological 
mechanisms, resulting in various deranged laboratory values. The wide range of different 
significantly predicted postoperative complications underlies the non-specificity of these 
measurements.
Albumin was in current study in multivariate analysis associated with pneumonia, how-
ever with insufficient discriminatory power. Generally albumin concentrations lower than 
25 g/l, are associated with postoperative pulmonary complications[8]. Serum albumin 
levels rapidly decrease as part of the acute phase response and its association with post-
operative complications may reflect as a marker of both malnutrition and the severity of 
host inflammatory response to the surgical insult[16]. Serum CRP and albumin levels, as 
incorporated into the Glasgow Prognostic Score, have shown to be an adequate prognos-
ticator in different types of cancer[19, 20].
Induced by proinflammatory cytokines, CRP is mainly synthesized in hepatocytes but it 
can also be produced by many other cell types, including liver and lung macrophages, 










































levels of CRP after a TTE are a part of a massive and immediate activation of the innate 
immunological response. However, it is difficult to distinguish between normal and abnor-
mal elevated CRP levels. However, in current study, the increased CRP levels compared to 
baseline values after 48 hours were related to infectious (i.e septic) complications. These 
results correspond to previous research, in which increased levels of CRP were associ-
ated with postoperative complications[10]. In a study of Noble et al., combined values of 
albumin, CRP and WBC were related to the development of anastomotic leakage, but only 
after the third postoperative day[11]. Since we analyzed up to 48 hours postoperatively, 
we could not confirm these outcomes. Instead, we found that anastomotic leakage was 
associated with raised LDH concentrations. This intracellular enzyme is present in all cell 
types and elevated LDH levels are measured in a wide variety of conditions. LDH may be 
also a useful marker to provide important information about ongoing cellular damage, 
such as in anastomotic area after revascularization. But further research is warranted to 
confirm this hypothesis.
In daily practice, creatinine is a fairly reliable indicator of renal function. In EC patients, 
preoperative elevated creatinine levels were associated with pulmonary complications 
and anastomotic leakage[15, 21]. And indeed a rising postoperative creatinine concentra-
tion reflects a poor hemodynamic condition, which makes it a strong prognostic marker.
In the treatment of EC patients, neoadjuvant CRT was found to be responsible for a more 
aberrant postoperative course[6, 22]. It probably induces a more pronounced influence 
on immunological function than surgery alone and should be part of further research[23]. 
In relation to peripheral blood values, neoadjuvant CRT was associated with decreased 
levels of creatinine, LDH, and hematopoietic changes. Other important patient- and treat-
ment related conditions in predicting postoperative complications were: smoking and side 
of thoracotomy.
Consequently, abnormal laboratory measurements after esophagectomy could be 
expected due to malnutrition, co-morbidity, neoplasm, age, neoadjuvant therapy and 
surgery-related conditions. In continuation with other studies in identifying complications 
early in the postoperative course, our observations indicate a more aberrant biochemical 
response in patients with postoperative morbidity and/or mortality. Moreover, we focused 
on the first 48 hours after esophagectomy to avoid bias resulting from blood sampling for 
specific complications or indications.
In conclusion, adequate interpretation of early deranged laboratory values after esopha-
gectomy remains difficult, but could indicate for a more aberrant postoperative course. 
Clinicians should be aware of postoperative complications in patients with deranged lev-
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objective: We aimed to provide prognostic value for cytokines concentrations on the 
degree of pathological response after neoadjuvant chemoradiotherapy (CRT) and oc-
currence of complications caused by either CRT or subsequent surgery at different time 
points in esophageal cancer (EC) patients.
Summary background data: Both CRT and subsequent esophagectomy are associated 
with release of multiple cytokines. This study provides more insight in the role of a num-
ber of cytokines throughout different phases in the multimodal treatment of EC patients.
Patients and methods: In a prospective observational study, 35 patients treated with plat-
inum-based neoadjuvant CRT followed by transthoracic esophagectomy were included. 
Nine different cytokine concentrations were determined during the combined therapy of 
neoadjuvant CRT with subsequent surgery and in the first postoperative week.
results: Intestinal fatty acid binding protein (I-FABP) increased (36 vs. 194 pg/ml; p < 0.001) 
during neoadjuvant CRT, but was not related to pathological response or complications. 
High concentrations of platelet activating factor (PAF) before and after neoadjuvant CRT 
were in ordinal logistic regression analysis associated with pathological response (OR: 
0.202; p = 0.006, respectively OR: 0.434; p = 0.015). Angiopoietin 1 (Ang-1) after neoad-
juvant CRT (OR: 0.382; p = 0.006), during surgical resection (OR: 0.687; p = 0.033 and OR: 
0.678; p = 0.040) and in the postoperative period (OR; 0.514; p = 0.031) was in multivari-
ate analysis associated with postoperative complications.
Conclusion: The unexpected rise of I-FABP after CRT point to early gastrointestinal dam-
age. High PAF concentrations before and after neoadjuvant CRT might have prognostic 











































In esophageal cancer (EC) patients, a combined treatment of neoadjuvant chemoradio-
therapy (CRT) followed by curative intended esophagectomy with two-field lymphadenec-
tomy is now standard of care in most centers. The beneficial effect of neoadjuvant CRT is 
based on the radio-sensitizing effect of combined chemotherapy, which allows improved 
resectability and a pathological complete response (pCR) rate of 15-30%12. Previous stud-
ies suggest that the prognosis of patients with pCR after neoadjuvant CRT may not benefit 
from subsequent surgery, while surgery in patients with insufficient or no response may 
be moved forward3, 4. Identifying these patients could be of great interest in further indi-
vidualizing treatment strategy. To date there are no useful biomarkers available related 
to the degree of tumor response, although some pro-inflammatory cytokines seem to 
play an active role56, 7. Induced immune response by preoperative CRT has been demon-
strated to change the levels of several soluble mediators, including interleukin (IL) 6 or 
inflammatory lipid metabolites such as platelet activating factor (PAF), which are related 
with both tumor response to treatment and tumor progression8-10. Furthermore, cytokine 
concentrations through all phases of the multimodality treatment might be correlated 
with the occurrence of complications caused by either CRT or surgery11.
Esophageal resection is associated with a considerable rate of postoperative morbidity 
(40-60%) and in-hospital mortality (3-5%)12, 13. This is partly due to extensive activation 
of leucocytes, macrophages and endothelial cells with enhanced expression and release 
of anti- and pro-inflammatory cytokines due to severe surgical trauma and the necessity 
of prolonged one-lung ventilation (OLV)1415. Patients with markers of increased systemic 
inflammation are known to have an increased risk for postoperative complications16. 
Although reported toxicity was acceptable during neoadjuvant CRT, the correlation of 
patient’s immunologic response in a multimodality treatment with early complications 
after subsequent surgery is not clear yet1.
In current study, we aimed to provide prognostic value for a number of cytokines with 
different pathophysiological mechanisms on the degree of pathological response on neo-
adjuvant CRT as well as the occurrence of complications caused by either CRT or subse-
quent surgery at different measure points. To our knowledge, this is the first longitudinal 
observational study that will give us more insight in immunological responses throughout 












































Between November 2011 and April 2013, we prospectively included 35 patients with his-
tologically proven EC selected for esophagectomy after approval by our multidisciplinary 
tumor board. Patient’s characteristics are described in Table 1. All patients received rou-
tine clinical care and no intervention was done for this study. In total, 262 blood samples 
were collected, with 53 (17%) missing values divided hazardly over the time points. The 
protocol was approved by the institutional review board (METC 2010.374) and all patients 
provided written informed consent.
Study design
To identify potentially prognostic cytokines for pathological response on preoperative 
CRT and postoperative complications of subsequent surgery, we included cytokines with 
different pathophysiological mechanisms. These included the pro-inflammatory markers 
interleukin (IL) 1β, IL-6, IL-8, tumor necrosis factor alpha (TNF-α), and procalcitonin, and 
the anti-inflammatory cytokine IL-10. Furthermore, two cytokines reflecting to endothe-
lial function, angiopoietin 1 (Ang-1) and platelet activating factor (PAF) were measured. As 
a marker of the integrity of the small and large intestine, we also measured the intestinal 
fatty acid binding protein (I-FABP) (Figure 1).
From all included patients, EDTA-serum samples (s) were obtained at nine predetermined 
time (T) moments (Figure 1); day 1, before neoadjuvant CRT (sT1), day 7 of CRT (sT2), prior 
before surgery (sT3), during two lung ventilation (sT4), during one lung ventilation (sT5), 
first (sT6), third (sT7), fifth (sT8), and seventh (sT9) postoperative day (Figure 1). Cytokine 
concentrations were determined by means of sandwich ELISA (Enzyme-Linked Immuno-
sorbent Assay) based on capture and biotin-labelled detection antibodies. D Streptavidin-
HRP and OPD substrate were used to quantify the amount of cytokines. Samples were 
diluted 1:1 in 0.1% BSA/PBS buffer, except for PAF, which was diluted 1:1000 in 0.1% BSA/
PBS buffer.
 










































Preoperative CRT consisted of carboplatin and paclitaxel with concurrent radiotherapy 
(CROSS scheme according to Chemoradiotherapy for Oesophageal Cancer Followed 
table 1. Patient’s characteristics
variable n = 35 (%)
Age in years (median) 64.9
Sex (M/F) 30/5 
histology
Adenocarcinoma 32 (91.4)
Squamous CC 3 (8.6) 
aSa classification
ASA I 5 (14.3)
ASA II 23 (65.7) 
ASA III 7 (20.0) 
Surgery
TTE right sided 22 (62.9)
TTE left sided 13 (37.1) 
Complications after neoadjuvant Crt
Minor complications 15 (42.9)
Moderate complications 2 (5.7) 
Pathological response*
Mandard 1 4 (11.4)
Mandard 2 6 (17.1) 
Mandard 3 13 (37.1) 
Mandard 4 11 (31.4) 
Mandard 5 1 (2.9) 
Complications
Respiratory failure 5 (14.3)
Pneumonia 17 (48.6) 
Re-intubation 5 (14.3) 
Arrhythmias 12 (34.3) 
Sepsis 2 (5.7) 
Anastomotic leakage 1 (2.9) 
Postoperative complications 18 (51.4) 
Surgical mortality** 3 (8.6) 
Postoperative course
Reoperation 2 (5.7)
OR-time (mean) 8.89 hrs 
ICU-stay (median) 1.0 days 
Hospital stay (median) 14.0 days 
ASA: American Society of Anesthesiologists. * According to the Mandard Classification










































by Surgery Study1). Oncologic criteria consisted of a clinical tumor stage of T1N1-3 or 
T2-T4aN0-3 without distant metastases (M0), according to the 7th TNM AJCC edition. 
Carboplatin (AUC 2) and paclitaxel 50 mg/m2 were administered weekly for 5 weeks. 
Radiotherapy consisted of 41.4 Gy in daily fractions of 1.8 Gy, five times per week.
Surgery
Patients were planned for a surgical resection with curative intent, usually within 4-8 
weeks after neoadjuvant CRT. All 35 patients underwent a transthoracic esophagectomy 
with two-field lymphadenectomy by two experienced surgeons in a high-volume center. 
All patients received orotracheal intubation using a double lumen tube for applying 
selective one-lung ventilation, which was based on pressure controlled ventilation with 
low tidal volumes (protective ventilation strategy). According to the protocol, all patients 
were intubated at transfer to the intensive care department, where they usually were 
detubated on indication and stay overnight.
Definitions of outcome
Pathological response to treatment was classified according to the commonly used 
Mandard classification varying from 1 (complete regression) to 5 (absence of regressive 
changes)17. Major pathological response was defined as Mandard 1, moderate as Mandard 
2/3 and minor response as Mandard 4/518. Complications from neoadjuvant CRT were 
scored according to the National Cancer Institute common toxicity criteria for adverse 
events (CTCAE version 4.03). Postoperative complications included pneumonia (defined 
as infiltration on X-ray, positive sputum culture, antimicrobial therapy for therapeutic pur-
pose), respiratory insufficiency (prolonged need for mechanical ventilation, re-admission 
on the ICU for respiratory support and/or re-intubation), sepsis (the clinical signs of SIRS 
i.e. systemic inflammatory response syndrome with culture-proven infection or infection 
identified by visual inspection), and anastomotic leakage (CT with oral contrast and el-
evated amylase in drainage fluid). Surgical mortality was defined as either death during 
the same hospital stay (in-hospital mortality) or within the first 90 days after surgery. 
Severity of co-morbidity was classified according to the American Society of Anesthesiol-
ogy (ASA) score varying from ASA 1 (very good condition) to ASA 5 (moribund patient).
Statistics
Results were presented as frequencies with percentages, means or medians. To deter-
mine the effect of different interventions on cytokine concentrations, changes after 
neoadjuvant CRT (sT1 vs. sT3), surgery (sT3 vs. sT6) and in the postoperative course (sT6 
vs. sT9) were analyzed with a paired sample t-test (normal distribution of the changes) 









































consequences, cytokine concentrations on sT1, sT2, and sT3 were in univariate analyses 
related to the three degrees of pathological response and complications after neoadju-
vant CRT. In addition, all time points were assessed whether they were associated with 
postoperative complications and outcomes with a p-value < 0.10 were further analyzed 
with multivariate logistic regression analysis and corrected for age, histology, cT-stage, 
ASA classification, and type of surgery. A p-value < 0.05 was considered to be significant. 
Statistical analyses were performed by using the Statistical Package for Social Sciences: 
SPSS version 20.0.0 (SPSS Inc., Chicago, IL USA).
reSultS
Major pathological response was observed in 11.4% (Mandard 1: N = 4), while 12 patients 
(34.2%) had minor or no response at all (Mandard 4/5; Table 1). Mild complications from 
neoadjuvant CRT occurred in 15 patients (42.9%), and two patients (5.7%) suffered from 
moderate complications (both thromboembolic process). More than half of this cohort 
suffered from postoperative complications (51.4%) (Table 1).
1. Cytokine concentrations during neoadjuvant CRT
Enhanced concentrations of I-FABP were observed during neoadjuvant CRT and showed to be 
significantly higher after neoadjuvant CRT (36.1 pg/ml vs. 193.9 pg/ml; p < 0.001) (Table 2). 
Remarkably, these elevated concentrations could not be related in univariate analysis to the 
degree of pathological response or complications after neoadjuvant CRT or surgery.
Ang-1 concentrations between sT1 and sT3 were not significantly different (3.4 ng/ml vs. 
3.9 ng/ml; p = 0.338) (Table 2, Figure 2). Nevertheless, a low concentration of Ang-1 after 














Ang-1 (ng/ml) 3.4 3.9 0.338 4.1 4.5 0.455 4.2 4.5 0.532
I-FABP (pg/ml) 36.1 193.9 0.000 212.7 56.3 0.000 50.5 35.4 0.494 
IL-1β (pg/ml) 14.5 13.9 0.702 15.6 14.3 0.700 29.8 25.9 0.032 
IL-6 (pg/ml) 20.3 15.5 0.687 23.5 489.4 0.000 377.7 204.8 0.018 
IL-8 (pg/ml) 7.7 12.0 0.055 12.6 6.7 0.355 11.3 9.6 0.560 
IL-10 (pg/ml) 32.8 46.0 0.581 50.6 62.2 0.009 62.8 38.5 0.022 
Procalcitonin (pg/ml) 4.7 4.4 0.983 4.3 104.9 0.000 106.2 10.3 0.000 
PAF (ug/ml) 4.8 5.3 0.046 5.3 4.7 0.024 4.6 5.2 0.013 










































neoadjuvant CRT (sT3) was associated with more severe postoperative complications in 
multivariate logistic regression analysis (odds ratio (OR): 0.382; 95% confidence interval 
(CI): 0.193-0.758; p = 0.006).
Concentrations of PAF were significantly elevated at the end of neoadjuvant CRT (4.8 ug/
ml vs. 5.3 ug/ml; p = 0.046) (Table 2). A sustained relatively high PAF concentration at 
the start and after neoadjuvant CRT was in multivariate ordinal regression analysis as-
sociated with major pathological response (OR: 0.202; 95% CI: 0.064-0.636; p = 0.006 





















 figure 2. Ang-1 concentrations (mean) related to postoperative complications throughout different 
phases of the treatment
 










































each degree of pathological response, only PAF concentrations after neoadjuvant CRT in 
patients with major pathological response were significantly elevated (mean sT1: 7.3ug/
ml vs. sT3: 9.1 ug/ml; p = 0.001).
Although IL-1β concentrations decreased during neoadjuvant CRT, none of the IL concen-
trations (1β, 6, 8, or 10), nor TNF-α or procalcitonin were statistically different between 
sT1 and sT3 or associated neither with the degree of tumor response nor with postop-
erative complications (Table 2). None of the examined cytokines were associated with 
complications during neoadjuvant CRT.
2. Cytokine concentrations during surgery
The surgical insult was responsible for large variations in most of these cytokines. Signifi-
cantly elevated concentrations after surgical resection (sT3 vs. sT6) were observed for IL-
6, IL-10, and procalcitonin. In assessing the effect of two and lung ventilation on cytokine 
concentrations, differences between sT4 and sT5 were examined and only IL-6 turned out 
to be significantly different (mean: 87.79 and 347.90 respectively, p = 0.021). Concentra-
tions of PAF and I-FABP were significantly decreased after surgical resection (Table 2). Of 
these cytokines, only Ang-1 was in multivariate logistic regression analysis (sT4 and sT5) 
related to postoperative complications (OR: 0.687; 95%CI: 0.486-0.970; p = 0.033 and OR: 
0.678; 95%CI: 0.468-0.983; p = 0.040 respectively).
3. Cytokine concentrations in the postoperative period
Many of the deviating concentrations after surgical resection returned to normal in the 
first postoperative week. Concentrations of IL-1β, IL-6, IL-10, procalcitonin, and TNF-α 
decreased significantly between sT6 and sT9. Concentrations of PAF were rising in this 
postoperative period (Table 2). In univariate analysis, concentrations of Ang-1 on sT7 
(p = 0.014), IL-6 on sT8 (p = 0.008) and sT9 (p = 0.011), and TNF-α on sT8 (p = 0.040) were 
associated with postoperative complications. However, in the multivariate logistic regres-
sion analysis, only Ang-1 was significantly associated with postoperative complications 
(OR; 0.514; 95%CI: 0.281-0.941; p = 0.031).
DISCuSSIon
Neoadjuvant CRT is a crucial component in the curative treatment of EC patients. It has 
been demonstrated to improve both disease free and overall survival considerably after 
radical transthoracic esophagectomy1. However, both are accompanied by extensive 
tissue damage and stress related severe immunological response with activation of sev-










































or stimulation of several growth factors and cell regulatory proteins9, 10, 14. A number of 
cytokines stimulate cell growth, including IL-1β and IL-6, while others induce or enhance 
toxicity during treatment (IL-6 and TNF-α), which triggers a cascade of inflamma-
tory pathways6, 8, 9, 19. The clinical relevance of cytokine activation and its correlation with 
pathological response and complications caused by either CRT or subsequent surgery in 
a multimodal treatment is not clear yet. Based on these concerns, we aimed to provide 
prognostic value for a number of cytokines throughout different presupposed time points 
in the treatment of EC patients.
Systemic effects of both chemotherapy and radiotherapy induce pro-inflammatory re-
sponses through IL-1β, IL-6, IL-8, and TNF-α within hours after exposure9, 20, 21, 19. However, 
in the present data we could not demonstrate differences in concentrations in none of 
these cytokines. In fact, we observed significantly elevated concentrations of I-FABP and 
PAF after CRT. Measurement of I-FABP seemed to be related to chemotherapy-induced 
gastrointestinal (GI) mucositis, as was described by Derikx et al.22. They observed a 
rapid increase of I-FABP early after damage of the mucosal cell integrity. The increased 
concentrations of I-FABP that we observed, apparently originated from the damaged GI-
tract, but could not be related to complications caused by CRT. The rapid decrease in the 
postoperative phase, even might suggest that the esophagus was the source of elevated 
I-FABP concentrations.
Besides significantly increased concentrations of PAF after neoadjuvant CRT, high PAF con-
centrations before and after CRT were associated with major pathological response. This 
may have clinical consequences, since these patients may not benefit from subsequent sur-
gery, while curative intended esophagectomy in patients with insufficient or no response 
may be moved forward. Through binding to PAF receptor (PAF-R), PAF has been shown to 
activate several pathways such as nuclear factor-kappa B (NF-κB)10, 23. PAF-R can augment 
chemotherapy-induced effects through NF-κB dependent process, which is accompanied 
with the release of cytokines10. Furthermore, PAF is produced by various tissues and cell 
types and in response to different stimuli, including oxidative stress23, 24. Both chemo- and 
radiotherapy are potent pro-oxidative stressors and during tumors growth, many cells die 
by apoptosis or necrosis which is accompanied by oxidation of membrane phospholipids. 
These apoptotic cells express PAF-like molecules23-25. Sakhi et al. concluded that elevated 
levels of antioxidant biomarkers before radiotherapy and increased oxidative stress dur-
ing radiotherapy may improve survival26. In the current study, we observed elevated PAF 
concentrations after CRT among all three groups (major, moderate and minor response), 
but only the major response group showed a significant difference. One of the possible 
explanations could be the release of PAF expressed by the massive amount of apoptotic 
tumor cells, while the initial response may be explained by NF-κB dependent process. 









































centrations could be of great importance and its association with pathological response 
needs to be confirmed in different cohorts before conducting with clinical consequences.
In contrast to I-FABP and PAF, concentrations of Ang-1 could not be related to CRT 
administration, but were related to postoperative complications in different phases of 
the treatment. Angiopoietin (1 and 2) is a growth factor that specifically binds to the 
endothelial receptor tyrosine kinase Tie-2. Ang-1 mediated Tie2 signaling will lead to the 
maintenance of cellular integrity and quiescence of the endothelial barrier by covering 
the vessel with periendothelial cells whereas Ang-2 mediated Tie2 signaling will lead to 
the removal of these cells27-29. Decreased concentrations of Ang-1 are related to infectious 
complications27, 28, 30. Although Ang-1 concentrations were not significantly different be-
tween start and end of neoadjuvant CRT, extensive apoptosis of vascular endothelial cells 
affects endothelial function, including promotion of vessel maturation through angiogen-
esis31. Ang-1 in the current study might be negatively associated with the inflammatory 
response to surgery, which results in increased vascular permeability and inflammation. 
This might lead to early identifications of patients with a severe systemic inflammatory 
distress syndrome.
Cytokine alterations after transthoracic esophagectomy have been extensively described 
and investigated22, 32, 33. Surgical stress and the necessity of OLV is responsible for a mas-
sive release of pro-inflammatory cytokines and a depressed host immune response by 
T helper type 1 (Th1) and 2 (Th2) cells1415. In the current study, we observed increased 
IL-6 concentrations between conventional two-lung ventilation and OLV, but since surgery 
was continued over time, we were not able to determine the real effect of OLV alone. 
Despite protective ventilation strategy, OLV is associated with operative hypoxemia due to 
shunting of blood via the non-ventilated lung as well as surgery-induced compression34. 
Hypoxemia causes a release of pro-inflammatory cytokines, which might result in the 
development of postoperative acute respiratory distress syndrome35. Further reduction 
of pro-inflammatory response and hypoxemia during surgical resection might be achieved 
by applying high frequency jet ventilation, which has been demonstrated as a safe and 
adequate ventilation technique during esophagectomy36.
Limited data is available about the influence of neoadjuvant CRT on cytokine production 
peri- and postoperatively21, 37. In rectal cancer patients a detrimental effect of preoperative 
CRT on postoperative cytokine release was demonstrated with depressed concentrations 
of IL-6 and TNF-α compared to patients without preoperative CRT20. In general, neoadju-
vant therapy is assumed to reduce Th1 and Th2 cytokine production leading to prolonged 
T cell imbalance that extends beyond the time of surgery21.
There are limitations in this study, since we included a relatively small number of patients. 
For this reason, coefficients in ordinal regression analysis may not be fully accurate and 










































therefore be interpreted as a pilot, whereby deduced hypotheses need to be confirmed 
in a large cohort.
In conclusion, cytokine concentrations in particular PAF and Ang-1, in patients treated 
with neoadjuvant CRT followed by esophagectomy for EC seems to have prognostic value 
on the degree of pathological response (PAF) and occurrence of postoperative complica-
tions (Ang-1). Concentrations of I-FABP were increased considerably after neoadjuvant 
CRT indicating to early GI damage. More research is necessary before these cytokines can 
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Summarizing discussion and future perspectives
Important improvements have been achieved in the past decades in staging and multi-
modality treatment of esophageal cancer (EC) patients1. Nevertheless, curative treatment 
for patients with EC remains challenging. Surgical resection, often preceded by neoad-
juvant chemoradiotherapy (CRT), is still the mainstay of treatment with curative intent, 
but is also associated with considerable postoperative morbidity (40-60%) and mortality 
(3-5%)2, 3. Many patients are over 60 years of age and presenting with associated co-
morbidity, which has an important impact on treatment decision-making. Several patients 
and tumor-related factors determine treatment outcome, but there are unfortunately to 
date no objective measurements available for an adequate risk-assessment of EC patients.
The aim of this thesis was to identify different risk-factors for perioperative morbidity 
and mortality during different phases in the standard treatment of esophageal cancer 
patients, which could provide us an additional tool for a better selection of patients to 
different curative intended treatment options.
Chapter 2 describes the influence of age on postoperative outcome after an extended 
transthoracic esophagectomy with two-field lymphadenectomy. Elderly patients, defined 
as ≥ 70 years of age, were compared to younger patients for comorbidity, postoperative 
course, recurrent disease and survival. We concluded that age alone is not a sufficient 
prognostic indicator for short- and long-term outcome after esophagectomy. Despite a 
twofold increased risk of in-hospital mortality in elderly patients, we could not observe 
significant differences. And although overall complications were statistically comparable, 
cardiac complications such as arrhythmia, and pulmonary complications, especially at-
electasis and respiratory insufficiency occurred more frequently in elderly patients. The 
presence of comorbidity was the strongest prognostic factor for the development of 
postoperative complications in this cohort. Moreover, long-term survival and recurrence 
rates were not related to the supposed disadvantage of elderly patients.
Both life expectancy and the incidence of EC are rising. Therefore, already in the near 
future, clinicians will be increasingly confronted with elderly patients with EC4. Denying 
surgery based on age alone seems not reasonable, but reticence is required in those 
with frailty due to co-morbidity, in particular based on cardiopulmonary dysfunction. In 
a review from 2013, authors concluded that elderly patients were at increased risk of 
pulmonary and cardiac complications, and perioperative mortality after esophagectomy5. 
Important improvements can be achieved in appropriate staging and selection of patients 
using optimal preoperative cardiopulmonary preparation. Severe pulmonary problems can 
be avoided by preoperative intensive muscle training and adequate epidural anesthesia.
Furthermore, different surgical approaches have been applied to reduce morbidity and 








































Summarizing discussion and future perspectives
gery is propagated as the surgical method to reduce perioperative risk in these high-risk 
surgical patients, but large-scale randomized controlled trials are needed to confirm this 
assumption6.
Since there is no adequate risk-prediction model in selecting patients for surgical resec-
tion, we attempted in Chapter 3 to find the currently most accurate risk-prediction model 
for postoperative morbidity and mortality after esophagectomy. Therefore, five of the 
most frequently used risk-prediction models including P-POSSUM and O-POSSUM modifi-
cations, Charlson Comorbidity Index (CCI) and its Age Adjusted Charlson Score (ACCI) and 
the standard American Society of Anesthesiologists (ASA) classification, were evaluated. 
Although each of these risk-prediction models showed some relation between postopera-
tive outcome and risk-score, we recommended O-POSSUM as individual risk stratification 
since it assessed the condition of the patient and the risk of surgery most accurately. 
For comparison between different cohorts, P-POSSUM was the most powerful predictor 
since it underestimated mortality by only one patient. For further applicability of clinical 
practice, we subdivided the O-POSSUM score in a low, intermediate and high-risk group. 
Despite these efforts, O-POSSUM is not generally used by clinicians, probably because of 
a lack of publicity. Instead, the most popular model of risk-assessment in daily practice is 
the ASA classification that excels in simplicity.
With multimodality treatment and a predominantly elderly population with considerable 
comorbidities, many factors could be associated with a complicated postoperative course. 
Therefore, identification of high-risk surgical patients remains difficult. With generally used 
ASA classification, we still have to deal with inter-observer dependent risk-assessment. 
With a more reliable score that realistically assess the magnitude of the therapy, we might 
even improve informed consent. Further research should be focused on already existing 
risk-adjusted models instead of developing new. In our opinion it is preferable to divide 
patients in risk-groups to improve informed consent and preoperative workup.
The incorporation of neoadjuvant CRT in the multimodality treatment of EC patients has 
dramatically increased in recent years. This is particularly due to the additional value of 
the Dutch national CROSS trial in which a significant survival benefit of 13% at 5 years 
after neoadjuvant CRT was demonstrated1. Although reported adverse events during neo-
adjuvant CRT were reported to be acceptable, other studies described an increased risk 
for thromboembolic toxicity as well as increased risk for postoperative complications7-10. 
Chapter 4 describes the incidence and impact of preoperative and postoperative throm-
boembolic events (TEE) in EC patients. Patients with neoadjuvant CRT were matched 
with patients who were treated with surgery alone. In accordance to our hypothesis, 








































Summarizing discussion and future perspectives
in the preoperative phase, especially in those with a previous history of TEE. Postopera-
tively we could not demonstrate any differences in the incidence of TEE’s between both 
groups. Although the majority of preoperative TEE’s were idiopathic and diagnosed during 
a second re-staging CT-scan, we recommend secondary prophylaxis during neoadjuvant 
CRT in patients with a previous history of TEE. We base this recommendation mainly on a 
guideline published in 2007 of the American Society of Clinical Oncology11. However, pro-
spective studies are needed to further define the use and safety of prophylactic therapy 
during platinum-based CRT in EC patients.
Other than the risk for a medical emergency, preoperative TEE’s will inevitably interact 
with the postoperative course since anesthesiologists are more reluctant to administer 
epidural analgesia under anticoagulation. Adequate postoperative analgesia is important 
after esophagectomy, because postoperative pain compromises pulmonary function, 
coughing, and mobilization. Adequate epidural analgesia is associated with a reduced risk 
for pulmonary complications12. Appropriate prevention is necessary to avoid anticoagula-
tory therapy resulting in the use of other strategies than epidural analgesia. Nevertheless, 
despite of a significantly longer delay until surgery in patients with preoperative TEE’s, we 
were not able to demonstrate any effect on the postoperative course.
Chemoradiotherapy prior for a radical esophagectomy might be associated with an 
increased risk for cardiopulmonary toxicity13-15. We evaluated in Chapter 5 the effect of 
neoadjuvant CRT on postoperative morbidity and mortality in a matched cohort after 
esophagectomy. In multivariate analysis, neoadjuvant CRT was significantly associated 
with an increased risk for pneumonia and arrhythmia. Overall complications were com-
parable between both groups, which was in accordance to the CROSS trial1. In literature, 
conflicting data have been reported about the impact of neoadjuvant CRT on postopera-
tive morbidity and mortality. However, the radiation exposure of heart and lungs during 
CRT is quite substantial and correlations between lower doses of radiotherapy are related 
to minimize the irradiation of the lungs13. Moreover, radiation to the pericardium might 
lead to an increased risk for pericardial effusion, which could be reflected in postoperative 
cardiac complications16. Therefore, further research should be focused on reduction of 
the amount of radiation on these organs, without compromising the beneficial effects of 
CRT. New and promising radiation techniques, such as proton beam therapy, could reduce 
cardiopulmonary toxicity.
Hospital volume is associated with improved short- and long-term outcomes in EC pa-
tients17. We hypothesized in a report (not included in this thesis) that surgeon-volume 
in a high-volume center is an additional independent prognostic factor for postoperative 
outcome after esophagectomy. In this report, we included two high-volume centers in the 








































Summarizing discussion and future perspectives
prognostic factor for the development of anastomotic leakage. Since we aimed to include 
a great part of the northern located centers in the Netherlands, further research will be 
carried out to determine the effect of surgeon volume in a large multicenter trial.
The effect of open transthoracic esophageal resection on early postoperative peripheral 
blood values and their association with postoperative morbidity and mortality was evalu-
ated in Chapter 6. A group of 210 consecutive EC patients underwent a radical transthoracic 
esophagectomy with curative intent. Standard peripheral blood values were acquired on 
three different time points with a maximum to 48 hours after resection. After multivariate 
analyses and ROC analysis, early deranged blood values of lactate dehydrogenase (LDH), 
creatinine, and C-reactive protein (CRP) were related to infectious complications after 
esophagectomy. Since major complications frequently interact with multiple pathophysi-
ological mechanisms, complications of various etiologies were associated with different 
deranged peripheral blood values. This underscores the non-specificity of these measure-
ments and the difficulty for a correct interpretation. Further research should be focused 
on more specific measurements to identify or predict postoperative complications in an 
early phase. Moreover, the pathophysiological mechanisms leading to a more aberrant 
postoperative course in patients is still not well understood. A better understanding and 
awareness might lead clinicians to start interventions earlier.
In Chapter 7 we evaluated nine cytokines that reflect different (patho)physiological re-
sponses to better understand the innate immunological response throughout different 
phases in the multimodal treatment of EC patients. In this hypothesis-generating study, 
we included 35 patients and performed multivariate analyses to assess the degree of 
pathological response after CRT and complications caused by either CRT or subsequent 
surgery to identify prognostic value for these cytokines. Concentrations of intestinal fatty 
acid binding protein (I-FABP) were considerably increased after neoadjuvant CRT indicat-
ing gastrointestinal damage, since I-FABP is released in the case of a damaged integrity 
of mucosal cells18. Remarkably, I-FABP levels were far lower after surgery. High concentra-
tions of platelet activating factor (PAF) before and after neoadjuvant CRT were related 
to major pathological response. Immunological pathways might also be responsible for 
augmentation of chemotherapy-induced effects of PAF through a nuclear factor-kappa B 
(NF-κB) dependent process19. Furthermore, apoptotic cells and oxidative stress can induce 
PAF and both radiotherapy and chemotherapy are known as potent oxidative stressors20. 
Finally we identified angiopoietin 1 (Ang-1) throughout different time points as an indi-
cator of postoperative complications. Ang-1 is involved in the maintenance of cellular 
integrity and quiescence of the endothelial barrier of vascular cells21. A decreased Ang-1 
concentration perioperatively could reflect an increased inflammatory response, which 








































Summarizing discussion and future perspectives
tion of release of pro-inflammatory cytokines during surgical procedure. High frequency 
jet ventilation (HFJV) might contribute to a reduction of pro-inflammatory response, since 
this ventilation technique prevents patients from shunting of the non-ventilated lung and 
is accompanied by low tidal volumes. Moreover, HFJV has been demonstrated as a safe 
and adequate ventilation technique during esophagectomy23. Since we evaluated these 
cytokine concentrations in a relatively small group of EC patients, large prospective trials 
are needed to confirm our hypotheses.
In conclusion, with this thesis we aimed to contribute to the knowledge of several treat-
ment related risk-factors in reducing perioperative morbidity and mortality in the stan-
dard curative treatment of esophageal cancer patients. Esophageal resection combined 
with neoadjuvant CRT should be initially considered in all medical fit and oncologically 
suitable patients. However, based on the outcomes of this thesis, clinicians should be 
aware of a complicated course due to side effects of CRT and patient and tumor-related 
characteristics. Individualizing treatment strategy remains an important target to improve 
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In het afgelopen decennium zijn belangrijke verbeteringen bereikt in de curatieve mul-
timodale behandeling van patiënten met een slokdarmcarcinoom1. Vele patiënten met 
een slokdarmcarcinoom zijn ouder dan 65 jaar en hebben een of meerdere bijkomende 
aandoeningen (co-morbiditeit). Een curatieve behandeling van het oesofaguscarcinoom 
blijft daarom in vele gevallen uitdagend. Een chirurgische resectie van de slokdarm, 
vaak voorafgaand door neoadjuvante chemoradiotherapie (CRT), blijft de belangrijkste 
behandelmodaliteit, maar gaat vaak gepaard met een aanzienlijk risico op postoperatieve 
morbiditeit (40-60%) en mortaliteit (3-5%)2, 3. Tot op heden is het helaas onduidelijk welke 
risicofactoren bijdragen aan een gecompliceerd perioperatief beloop.
Het doel van dit proefschrift was om verschillende risicofactoren te identificeren die 
voorspellend zijn voor perioperatieve morbiditeit en mortaliteit gedurende verschillende 
fasen in de behandeling van patiënten met een slokdarmcarcinoom.
In hoofdstuk 2 beschrijven we de invloed van leeftijd op de postoperatieve uitkomst na 
een transthoracale slokdarmresectie. Oudere patiënten (gedefinieerd als 70 jaar en ouder) 
werden vergeleken met jongere patiënten met betrekking tot comorbiditeit, postoperatief 
beloop, optreden van recidieven en de lange termijn overleving. We concludeerden in dit 
onderzoek dat leeftijd geen onafhankelijke voorspellende factor is voor korte -en lange 
termijn uitkomst na een slokdarmresectie. Patiënten met een of meerdere comorbiditeiten 
hadden het hoogste risico op postoperatieve complicaties. Ondanks het ontbreken van een 
significant verschil, was het percentage oudere patiënten die in het ziekenhuis overleed ten 
gevolge van de operatie ruim twee keer zo hoog. Het totaal aantal postoperatieve compli-
caties tussen beide groepen was vergelijkbaar, maar cardiale complicaties (in het bijzonder 
hartritmestoornissen) en pulmonale complicaties (vooral atelectase en respiratoire insuffi-
ciëntie) kwamen vaker voor in oudere patiënten. Er was geen significant verschil in de lange 
termijn overleving en het aantal recidieven in oudere patiënten vergeleken met jongere pa-
tiënten. Gezien het feit dat de levensverwachting en de incidentie van slokdarmcarcinomen 
stijgt, zullen clinici vaker geconfronteerd worden met oudere patiënten4. Selecteren van 
patiënten voor een slokdarmresectie alleen gebaseerd op de leeftijd lijkt niet redelijk, maar 
terughoudendheid is vereist bij patiënten met comorbiditeit. Belangrijke verbeteringen zijn 
mogelijk in een adequate selectie en optimale preoperatieve cardiopulmonale voorberei-
ding5. Bovendien zou minimaal invasieve chirurgie kunnen bijdragen aan een verminderde 
perioperatief risico op morbiditeit en mortaliteit in risicovolle chirurgische patiënten6. 
Grootschalige gerandomiseerde studies zijn nodig om deze veronderstelling te bevestigen.
Tot op heden bestaat er geen goed model in het selecteren van chirurgische patiënten; 









































O-POSSUM, Charlson Comorbiditeit Index (CCI), de op leeftijd aangepaste Charlson 
Score (ACCI) en de American Society of Anesthesiologists (ASA) classificatie, te evalueren. 
Ondanks dat alle modellen in meer of mindere mate een redelijke voorspelling deden 
van het postoperatieve risico, concludeerden we dat O-POSSUM het meest nauwkeurige 
model was voor de individuele risico-inschatting. Voor de vergelijking tussen verschillende 
cohorten, bleek P-POSSUM de meest nauwkeurige voorspeller te zijn, omdat dit model 
de totale sterfte met slechts één patiënt onderschatte in ons cohort. Ter verbetering van 
de klinische toepasbaarheid, hebben we de O-POSSUM score onderverdeeld in een laag, 
gemiddeld en hoog risicogroep. Desondanks wordt de O-POSSUM score nog niet in de 
dagelijkse praktijk gebruik, mogelijk door een gebrek aan publiciteit. In plaats daarvan 
wordt de ASA classificatie frequent gebruikt, die uitblinkt in eenvoud.
Met de huidige multimodale behandeling kunnen meerdere factoren van invloed zijn op 
een gecompliceerd postoperatieve beloop. De identificatie van een risicovolle chirurgische 
patiënt blijft daarom moeilijk. Aangezien momenteel de ASA classificatie frequent gebruikt 
wordt, is de risico-inschatting onderhevig aan subjectieve waarnemingen. Daarnaast kan 
een eenduidige risicoanalyse die een realistisch beeld geeft van de omvang van de behan-
deling ook bijdragen aan een verbeterde informed consent. Verder onderzoek zou gericht 
moeten zijn op al bestaande risicoanalyse modellen. Naar onze mening zouden patiënten 
ingedeeld moeten worden in risico-groepen waarmee informed consent en preoperatieve 
voorbereiding verbeterd kunnen worden.
De invloed van neoadjuvante CRT in de multimodale behandeling van patiënten met een 
slokdarmcarcinoom is in de afgelopen jaren spectaculair toegenomen. Voor een deel is 
dit toe te schrijven aan een groot nationaal onderzoek (CROSS trial) waarbij de auteurs 
een significant overlevingsvoordeel van 13% hebben aangetoond na vijf jaar1. Ondanks 
dat de gerapporteerde bijwerkingen in dit onderzoek door CRT aanvaardbaar waren, heb-
ben verschillende andere studies een verhoogd risico op trombo-embolische toxiciteit 
evenals een verhoogd risico op postoperatieve complicaties beschreven7-10. hoofdstuk 
4 beschrijft de incidentie van pre -en postoperatieve trombo-embolische processen in 
patiënten met een slokdarmcarcinoom. In dit onderzoek werden patiënten met neoadju-
vante CRT gematcht met patiënten die alleen een slokdarmresectie hadden ondergaan. In 
overeenstemming met onze hypothese, werd neoadjuvante CRT geïdentificeerd als een 
onafhankelijke prognostische factor voor de ontwikkeling van trombo-embolische proces-
sen in de preoperatieve fase en vooral bij patiënten met een belaste voorgeschiedenis 
voor trombo-embolische processen. De postoperatieve incidentie van trombo-embolische 
processen tussen beide groepen was gelijk. Ondanks dat de meerderheid van de preope-
ratieve trombo-embolische processen zonder klinische klachten gepaard gingen en bij 









































dit onderzoek secundaire profylaxe aan tijdens neoadjuvante CRT bij patiënten met een 
belaste voorgeschiedenis. Deze aanbeveling werd vooral gebaseerd op een richtlijn uit 
2007 van de American Society of Clinical Oncology11. Prospectieve onderzoeken zijn nodig 
om het gebruik en de veiligheid van profylactische therapie gedurende neoadjuvante CRT 
te evalueren.
Preoperatieve trombo-embolische processen kunnen, behalve het risico op een medische 
noodsituatie, ook invloed hebben op het postoperatieve beloop, aangezien anesthesisten 
terughoudend zijn om epidurale analgesie toe te passen onder bepaalde vormen van an-
tistolling. Postoperatieve pijnstilling is van groot belang na een slokdarmresectie, omdat 
postoperatieve pijn gepaard kan gaan met een verminderde longfunctie, pijn bij hoesten, 
en een afnemende mobilisatie. Een goed werkende epidurale pijnstilling is geassocieerd 
met een verminderd risico op pulmonale complicaties12. Adequate trombo-embolische 
preventie is dus noodzakelijk om te voorkomen dat er een ander beleid dan epidurale 
analgesie wordt gevoerd. We konden echter geen verschil aantonen in het postoperatieve 
beloop bij patiënten met een preoperatief trombo-embolische proces.
Chemoradiotherapie voorafgaand aan een slokdarmresectie wordt verondersteld gepaard 
te gaan met een verhoogd risico op cardiopulmonale toxiciteit13-15. In hoofdstuk 5 hebben 
we het effect van neoadjuvante CRT op postoperatieve morbiditeit en mortaliteit in een 
gematchte groep na een slokdarmresectie geëvalueerd. Na multivariate analyse bleek 
neoadjuvante CRT significant geassocieerd met een verhoogd risico op de ontwikkeling 
van longontstekingen en hartritmestoornissen. Het totaal aantal complicaties was verge-
lijkbaar in beide groepen, in overeenstemming met het CROSS onderzoek1. De afgelopen 
jaren zijn tegenstrijdige resultaten gerapporteerd over de invloed van neoadjuvante 
CRT op postoperatieve morbiditeit en mortaliteit. De stralingsdosis op cardiopulmonale 
organen tijdens neoadjuvante CRT is echter substantieel. Er zijn onderzoeken die een cor-
relatie tussen een lagere stralingsdosis en een vermindering van de pulmonale belasting 
laten zien13. Bovendien zou bestraling van het pericard leiden tot een verhoogd risico op 
pericardvocht, zich mogelijk uitend in postoperatieve cardiale complicaties16. Vervolgon-
derzoek zou zich dan ook moeten richten op bestralingsmethoden, die leiden tot minder 
schadelijke bijwerking van de straling op deze organen, zonder afbreuk te doen aan de 
gunstige effecten van CRT. Veel belovende stralingstechnieken zoals protonentherapie, 
kunnen cardiopulmonale toxiciteit verminderen.
Ziekenhuis volume wordt geassocieerd met verbeterde korte en lange termijn uitkomsten 
in patiënten met een slokdarmcarcinoom17. In een verslag (niet opgenomen in dit proef-
schrift) hebben we verondersteld dat het aantal uitgevoerde operaties door een chirurg 









































operatieve uitkomst na een slokdarmresectie. In dit verslag hebben we twee hoog-volume 
ziekenhuizen in Nederland geïncludeerd en na multivariate analyses, bleek het aantal 
uitgevoerde operaties door een chirurg de enige onafhankelijke prognostische factor te 
zijn voor een naadlekkage. Ons doel is echter om een groot deel van de noordelijk gelegen 
centra in Nederland te includeren, vervolg onderzoek zal hier dan ook op gericht zijn.
Het effect van een slokdarmresectie op vroege postoperatieve labwaarden en de associ-
atie met postoperatieve morbiditeit en mortaliteit werd geëvalueerd in hoofdstuk 6. Een 
groep van 210 opeenvolgende slokdarmpatiënten onderging een radicale transthoracale 
resectie. Standaard afgenomen labwaarden werden op drie verschillende tijdstippen ge-
includeerd met maximum tot 48 uur na de operatie. Multivariate analyses en ROC analyse 
toonden prognostische waarde voor lactaat dehydrogenase (LDH), creatinine en C-reactief 
proteïne (CRP) voor het ontstaan van infectieuze complicaties na een slokdarmresectie. 
Ernstige complicaties integreren met meerdere pathofysiologische mechanismen, die zich 
uiten middels verschillende afwijkende labwaarden. Dit bevestigt het niet-specifieke ka-
rakter van deze waarden en de daaraan gerelateerde lastige interpretatie. In dit onderzoek 
attenderen we clinici er op zich bewust te zijn van een mogelijk gecompliceerd postope-
ratieve beloop en een zo nodig vroege interventie indien deze waarden afwijkend blijken 
te zijn. Verder onderzoek moet gericht zijn op meer specifieke markers om postoperatieve 
complicaties in een vroeg stadium te identificeren. Bovendien zijn de pathofysiologische 
mechanismen die leiden tot een gecompliceerd postoperatief beloop nog steeds niet 
goed duidelijk. Een verbeterde kennis zou kunnen leiden tot vroegtijdige interventies.
In hoofdstuk 7 hebben we negen cytokines geëvalueerd met verschillende (patho)
fysiologische mechanismen om meer inzicht te verschaffen in de immunologische reactie 
gedurende verschillende fasen in de multimodale behandeling van slokdarmpatiënten. 
In deze hypothese genererende studie hebben we 35 patiënten geïncludeerd. Om de 
prognostische waarde te bepalen van deze cytokines met betrekking tot de pathologische 
respons na CRT en de complicaties veroorzaakt door CRT of de daaropvolgende opera-
tie, hebben we multivariate analyses uitgevoerd. Concentraties van intestinal fatty acid 
binding protein (I-FABP) namen na neoadjuvante CRT aanzienlijk toe, duidend op aan 
de behandeling gerelateerde toxische gastrointestinale beschadiging, aangezien I-FABP 
vrijkomt bij een beschadigde integriteit van mucosale cellen18. Na chirurgie namen de 
concentraties I-FABP juist weer sterk af. Hoge concentraties van platelet activating fac-
tor (PAF) voor en na neoadjuvante CRT waren gecorreleerd aan pathologische respons. 
Mogelijk is dit effect gerelateerd aan toegenomen chemotherapie-geïnduceerde effecten 
van PAF door activering van immunologische pathways19. Bovendien komt PAF vrij bij de 
apoptose van tumor cellen en tijdens oxidatieve stress en zowel radiotherapie als che-









































een prognostische marker voor postoperatieve complicaties gedurende verschillende 
fasen in de multimodale behandeling. Ang-1 is betrokken in het handhaven van de cel-
lulaire integriteit en endotheliale barrière van vasculaire cellen21. Een verlaagde Ang-1 
concentratie perioperatief, gerelateerd aan een verhoogde ontstekingsreactie, kan leiden 
tot verhoogde vasculaire permeabiliteit22. Verder onderzoek zou gericht moeten zijn 
op vermindering van de afgifte van pro-inflammatoire cytokines tijdens de chirurgische 
procedure. Hoog frequente jet ventilatie (HFJV) kan wellicht een bijdrage leveren aan een 
vermindering van deze respons. Deze ventilatietechniek voorkomt dat patiënten shunten 
over de niet-geventileerde long en gaat tevens gepaard met lage teugvolumes. Bovendien 
is aangetoond dat HFJV een veilige ventilatietechniek is tijdens een slokdarmresectie23. 
Bovenstaande hypothesen zijn gebaseerd op een relatief kleine groep patiënten, grote 
prospectieve studies zijn dan ook nodig om gegenereerde hypothesen te bevestigen.
In conclusie, met dit proefschrift hebben we beoogd meer inzicht te geven in de mogelijke 
risicofactoren die betrokken zijn in de relatieve hoge perioperatieve morbiditeit en mor-
taliteit bij in opzet curatieve behandeling van patiënten met een slokdarmcarcinoom. Een 
curatieve behandeling, bestaande uit een slokdarmresectie gecombineerd met neoadju-
vante CRT, zal bij elke medisch fitte en op oncologische basis geselecteerde patiënt over-
wogen worden. De uitkomsten van dit proefschrift zullen er toe leiden dat clinici zich meer 
bewust zijn van welke behandeling-, patiënt,- en tumor-gebonden factoren betrokken zijn 
bij een mogelijk gecompliceerd beloop. Individualiseren van het behandelprotocol blijft 
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Zonder hulp van anderen was dit proefschrift niet verschenen. Graag zou ik van de gele-
genheid gebruik willen maken om enkele personen in het bijzonder te bedanken.
Allereerst natuurlijk mijn eerste promotor, prof. dr. J.Th.M. Plukker. Beste John, als 3e jaars 
geneeskundestudent startte ik onder jouw bezielende begeleiding met wetenschappelijk 
onderzoek. Direct wist je mijn onderontwikkelde wetenschappelijke snaar te raken en 
werkte jouw gedrevenheid aanstekelijk. Je bent daarna dan ook niet meer van mij afgeko-
men. De mogelijkheden die je mij bood en de ruimte die je mij gaf om mijn eigen pad te 
kunnen bewandelen, heb ik vanaf het begin zeer gewaardeerd. In een later stadium gaf je 
mij het vertrouwen om andere beginnende studenten te begeleiden bij hun wetenschap-
pelijke vorming. Des te meer werd mij duidelijk welke eigenschappen er worden verwacht 
van een goede begeleider en des te meer waardering kreeg ik voor je snelle reacties, tijd 
en aandacht.
Naast wetenschappelijke vorming heb ik ook veel van je mogen leren als het gaat om de 
omgang met collega’s en patiënten. Als arts-assistent op de IC heb ik de betrokkenheid die 
jij naar je patiënten toonde als een groot voorbeeld gezien. Bijzonder vond ik ook dat wij 
bij jouw inauguratie aanwezig mochten zijn en ook onze gezamenlijke tripjes naar Amerika 
zal ik niet snel vergeten. Kortom beste John, ik ben trots dat je mijn eerste promotor wilde 
zijn, waarvoor mijn dank zeer groot is!
Mijn tweede promotor, prof. dr. M.M.R.F. Struys. Beste Michel, al direct tijdens onze eer-
ste afspraak werd mij duidelijk dat je veel waarde hecht aan wetenschappelijk onderzoek. 
De mogelijkheden die je voor mij creëerde heb ik zeer gewaardeerd. Daarnaast heb je mij, 
toen de finish in zicht kwam, van snel en duidelijk commentaar voorzien, waarvoor mijn 
uitgesproken dank.
Naast onze reeds prettige samenwerking, zal de nadruk vooral op de toekomst gericht zijn. 
Als arts-assistent binnen de anesthesiologie hoop ik de aankomende jaren veel van je te 
mogen leren. Daarnaast zou ik een verdere wetenschappelijke samenwerking ambiëren.
Mijn copromotor, dr. M.W.N. Nijsten. Beste Maarten, in het bijzonder zou ik je willen 
bedanken voor je snelle en duidelijke feedback. Je verbeteringen waren vaak de spreek-
woordelijke “spijker op z’n kop”. Maar ook je statistische kennis en betrokkenheid ten tijde 
van mijn aanstelling als arts-assistent op de IC heb ik zeer gewaardeerd. Ik heb veel van je 
geleerd, dank daarvoor.
Graag zou ik de leden van de beoordelingscommissie, prof. dr. A.R.J. Girbes, prof. dr. J.G. 










































Veel bewondering heb ik voor de patiënten die besloten deel te nemen aan mijn onder-
zoeken. Ondanks de moeilijke en onzekere tijd waarin zij verkeerden, besloten zij een 
bijdrage te willen leveren aan de wetenschap. Ik ben u allen zeer erkentelijk voor uw 
bijdrage en wens u en uw familie het allerbeste.
Beste prof. dr. G.A.P. Hospers en drs. V.E.M. Mul. Beste Geke en Véronique, bedankt voor 
de plezierige samenwerking, snelle reacties en opbouwende kritiek.
Beste co-auteurs, bedankt voor de fijne samenwerking en jullie bijdrage aan dit proef-
schrift!
Beste Ida van Til, jij verdient zeker een plaats in deze lijst. Heel erg bedankt voor je flexibi-
liteit en het regelen van de bloedafnames.
Jan-Binne Hulshoff, Rens van der Linde, Robbert-Jan Lindeman en Hylke Brenkman be-
dankt voor het verzamelen van de bloedbuisjes! Jullie hebben een belangrijke bijdrage 
geleverd aan een deel van dit proefschrift.
Kamer E2.18. Beste Bastiaan Pultrum, Justin Smit, Maarten Niebling, Judith Honing, Dane 
Hoeksma en Leon van Dullemen, vier jaar van mijn leven waren een stuk saaier geweest 
zonder jullie aanwezigheid. Het is fijn om te weten dat ik niet de enige ben die zoveel 
onzin op een dag kan verkondigen. Misschien stond ik niet altijd even sterk (of juist wel?) 
op mijn benen tijdens onze trip naar Washington, maar wat was het briljant om met jul-
lie (Maarten Niebling, Kevin Wevers en de fiscus alias Lars Steggink) een weekje “lekker 
Amerikaans” te doen.
Mijn beide paranimfen, Marc Bosch en Freek Brandts, bedankt dat jullie bereid zijn om mij 
bij te staan tijdens mijn promotie. Beste Marc, als jongste broertje hebben wij altijd een 
bijzondere band gehad die me erg dierbaar is. Beste Freek, als clubgenoten hebben wij 
al meerdere zeeën bevaren en zelfs na meer dan een jaar als huisgenoten zijn we elkaar 
nog steeds niet zat.
Lieve ouders, promoveren en de familie Bosch blijken niet altijd even gelukkig samen te 
gaan. Maar zonder tegenslagen leer je niet te genieten van de mooie momenten (stelling 
12) en die hebben we gelukkig in overvloed! Samen met Tjitske en Hidde prijs ik mij intens 
gelukkig met jullie aan mijn zijde. Het mag een understatement zijn dat jullie een grote 
inspiratiebron voor mij zijn. Ik wil jullie heel erg bedanken voor jullie vertrouwen in mijn 









































Lieve Tjitske en Hidde, het is onbeschrijfelijk wat jullie in mij losmaken. Ik vraag mij wel-
eens af of ik nog trotser of gelukkiger kan worden en elke keer denk ik dat het jullie weer 
gelukt is. Ik hoop dat jullie me nog heel vaak blijven verrassen en dat we nog heel lang van 
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